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ABSTRACT OF DISSERTATION
MOLECULAR  AND CELLULAR CHARACTERIZATION OF THE DOPAMINE 
NEURON STIMULATING PEPTIDES
Parkinson’s disease, the second most common neurodegenerative disease, 
is characterized by the loss of dopaminergic neurons within the substantia nigra.  
Currently, the treatments available for PD are symptomatic treatments that do not 
stop the progression of the disease.  Trophic molecules, such as glial cell-line 
derived neurotrophic factor (GDNF), have been evaluated as potential 
therapeutic molecules that could stop the loss of neurons and potentially restore 
some of the neurons that have already been lost.  However, these trophic 
molecules are large making them difficult to produce and delivery.  Here we 
characterize three peptides (DNSP-5, DNSP-11, and DNSP-17) to determine it 
they are stable and offer protective effects similar to GNDF allowing them to be 
potential therapeutic molecules.  
The data presented here involves the evaluation of the molecular and cellular 
mechanism of DNSP-5, DNSP-11, and DNSP-17, which are derived from 
prosequence of GDNF.  Initial studies were carried out to evaluate the physical 
characteristics of these three peptides to determine their viability as potential 
therapeutic molecules.  The structure and stability of these peptides were 
evaluated.  Based on the data it was determined that the three peptides do not 
interact in vitro, allowing for further individual evaluations of the peptides.  It was 
also determined that the peptides were stable when stored at both -80°C and 
37°C for one month, allowing them to both potentially be stored during treatment.
Cell culture assays and proteomic profiling were utilized to determine binding 
partners and potential mechanisms through which DNSP-11 may be able to 
mediate apoptosis.  It was determined that DNSP-11 was able to interact with a 
variety of binding partners that are involved in metabolism.  These studies have 
aided in the understanding of neurotrophic factor prosequence function, but will 
also serve as a starting point for the development of novel trophic factors for PD 
treatment.  
Finally, the interaction between DNSP-11 and GAPDH was evaluated as a 
potential anti-apoptotic mechanism.  GAPDH has previously shown to play a role 
in mediating apoptotic pathways.  It was hypothesized that the observed 
interaction between DNSP-11 and GAPDH could mediate that role of GAPDH in 
apoptosis and afford DNSP-11 its observed anti-apoptotic effects.  It was 
observed that while DNSP-11’s interaction with GAPDH may play a role in its 
anti-apoptotic effects, it does not appear to be the only mechanism involved.  
Based on this data, it is likely that the other metabolic binding partners play a role 
in DNSP-11’s anti-apoptotic mechanisms and therefore, these interactions should 
be further evaluated.
KEYWORDS: GDNF, DNSP-11, GAPDH, Anti-apoptotic, Peptides
Kristen Kelps
Student’s Signature
December 17, 2013
Date
MOLECULAR  AND CELLULAR CHARACTERIZATION OF THE DOPAMINE 
NEURON STIMULATING PEPTIDES
By
Kristen Alice Kelps
Co-Director of Dissertation
Director of Graduate Studies
Co-Director of Dissertation
Luke Bradley, PhD
Don Gash, PhD
Wayne Cass, PhD
December 17, 2013
The dissertation is dedicated to my granddad, Donald Lambert, for constantly 
stressing the importance of education.
ACKNOWLEDGEMENTS 
First, I would like to thank my mentor, Luke Bradley, Ph.D., for being 
willing to allow me to work in his laboratory as a graduate student.  His continued 
support throughout this process has played a pivotal role in my growth as a 
scientist and educator.  His encouragement has enabled me to successfully 
prepare for and start down my desired career path.  
I would also like to express my gratitude to the rest of my graduate 
committee, Don Gash, Ph.D., Greg Gerhardt, Ph.D., Louis Hersh, Ph.D., Hans 
Bueler, Ph.D., and Richard Grondin, Ph.D.  Their guidance, insight, and 
encouragement have been an essential part of my growth and progress.  I would 
like to thank Dr. Don Gash for being willing to serve as the co-chair of my 
graduate committee.
Additionally, there have been numerous other people that played key roles 
in the completion of my research.  I would like to thank Jadwiga Turchan-
Cholewo, Ph.D. for sharing her vast knowledge of cell culture with me.  I would 
also like to thank Charlotte Randle for her patience, encouragement, and great 
advice.  The collaborations with the Gash and Gerhardt laboratories has been an 
important part of the completion of the research presented here.  I would also like 
to thank the undergraduate students that I had the privilege to work with in the 
laboratory, including Michael Bricken, Sudipa Chowdhury, Tiffany Taylor, and 
Alyssa Fountain Antonicello.  I would also like to thank the UK Center of 
Structural Biology and Carol Beach, Ph.D. for assistance with the mass 
spectroscopy presented here.  Also, sincere thanks go out to all the 
iii
administrative staff within the Anatomy & Neurobiology Department for the 
continued willingness to answer my numerous questions.
Finally, I would like to thank my family and friends for their continued love 
and support throughout this process, especially my parents, Ken and Debbie 
Kelps, for their constant encouragement.  I would also like to extend a special 
thank you to Shane Davison for assisting with the editing of the document.  I 
would also like to give thanks to an amazing group of friends who have served as 
support group throughout this experience.
iv
TABLE OF CONTENTS
Acknowledgments.................................................................................................iii
List of Figures.......................................................................................................vii
List of Tables.........................................................................................................ix
Chapter One: Introduction.....................................................................................1
Overview................................................................................................................1
Introduction to Parkinson’s disease.......................................................................1
Background/History.....................................................................................1
Pathophysiology..........................................................................................3
Loss of dopaminergic neurons.........................................................3
Lewy body formation........................................................................3
Other deficits....................................................................................4
Etiology.......................................................................................................5
Genetics...........................................................................................5
Environmental..................................................................................9
Excitotoxicity...................................................................................13
Inflammation...................................................................................13
Treatments................................................................................................14
Symptomatic treatments.................................................................14
Physical therapy and surgical treatments.......................................16
Growth factors................................................................................17
Role of growth factors in the treatment of neurodegenerative 
diseases..............................................................................17
Glial cell line-derived neurotrophic factor............................20
Clinical trials of GDNF.........................................................22
Challenges of growth factors...............................................................................23
Large size-difficult to deliver.....................................................................23
Delivery methods......................................................................................24
Convection enhanced delivery.......................................................24
AAV, Adenovirus, Lentivirus...........................................................26
Other neurotrophic factors.............................................................27
Biotherapeutic strategies.....................................................................................28
Peptides offer attractive molecular advantages...................................................30
Chemical synthesis...................................................................................31
Modification...............................................................................................31
Peptide signaling molecules.....................................................................32
Growth factor prosequences...............................................................................33
Role in apoptosis......................................................................................33
DNSP-11..............................................................................................................34
Processing................................................................................................35
Potential as a therapeutic.........................................................................35
DNSP-11 and GAPDH..............................................................................37
v
Thesis outline......................................................................................................38
Chapter Two: Methods.........................................................................................49
Stability study.......................................................................................................49
Far-UV circular dichroism spectroscopy..............................................................49
Heparin affinity chromatography..........................................................................50
Caspase-3 activity assay.....................................................................................50
Terminal dUTP nick-end labeling (TUNEL)..........................................................51
Pull down analysis with isolated substantia nigra from young Fischer 344 
rats.......................................................................................................................51
In vitro pull down of GAPDH................................................................................52
In vitro S-nitrosylation of GAPDH.........................................................................52
In vitro pull down assay........................................................................................53
Western blots.......................................................................................................53
Chapter Three: Evaluation of the physical and in vitro protective activity of three 
synthetic peptides derived from the pro- and mature GDNF sequence...............54
Introduction..........................................................................................................54
Methods...............................................................................................................56
Stability study............................................................................................56
Far-UV circular dichroism spectroscopy....................................................57
Heparin affinity chromatography................................................................57
Caspase-3 activity assay...........................................................................58
Results.................................................................................................................58
RP-HPLC analysis and long-term stability of the DNSPs.........................58
Far-UV circular dichroism structural analysis............................................59
Heparin binding analysis...........................................................................60
Protection from staurosporine and 3-nitropropionate in HEK-293 cells....60
Discussion............................................................................................................62
Conclusion...........................................................................................................66
Chapter Four: Role of GAPDH in DNSP-11 protection........................................73
Introduction..........................................................................................................73
Methods...............................................................................................................77
Capase-3 activity assay............................................................................77
Terminal dUTP nick-end labeling (TUNEL)...............................................78
Pull down analysis with isolated substantia nigra from young Fischer 344 
rats............................................................................................................78
In vitro pull down of GAPDH.....................................................................79
In vitro S-nitrosylation of GAPDH.............................................................79
In vitro pull down assay............................................................................80
Western blots...........................................................................................80
Results................................................................................................................81
DNSP-11 reduces apoptosis....................................................................81
DNSP-11 does not bind GFRα1...............................................................82
DNSP-11 does not upregulate GDNF mRNA levels.................................83
vi
DNSP-11 does not upregulate GDNF protein levels.................................83
Proteomic analysis....................................................................................84
Confirmation of GAPDH-DNSP-11 binding...............................................86
Nitrosylation of GAPDH decreases DNSP-11 binding..............................86
DNSP-11 reduces nitrosylation of GAPDH...............................................87
Alteration of nuclear GAPDH levels..........................................................88
Discussion...........................................................................................................90
Conclusion...........................................................................................................96
Chapter Five: Conclusions and future directions...............................................113
Introduction........................................................................................................113
Introduction of alternative mechanisms.............................................................113
Metabolic binding partners.................................................................................115
Glutamate deydrogenase........................................................................116
Mitochondrial interactions...................................................................................117
Combination of mechanisms..............................................................................119
Future directions.................................................................................................119
GAPDH....................................................................................................119
C150 mutation of GAPDH experiments..................................................120
Glutamate dehydrogenase.....................................................................121
Evaluation of other binding partners.......................................................121
References........................................................................................................123
Vita.....................................................................................................................146
vii
LIST OF TABLES
Table 1.1: Genetics of Parkinson’s disease.........................................................41
Table 1.2: Current Parkinson’s disease treatments.............................................42
Table 1.3: Interaction of dopamine agonists with dopamine receptors................44
Table 3.1: Characterization of the DNSPs in vitro stability after incubation at 
37°C for 31 days..................................................................................................69
Table 4.1: Potential binding partners for DNSP-11.............................................104 
viii
LIST OF FIGURES
Figure 1.1: The history of Parkinson’s disease....................................................39
Figure 1.2: Changes in signaling in the basal ganglia in Parkinson’s 
disease.................................................................................................................40
Figure 1.3: Mechanisms of current Parkinson’s disease treatments....................43
Figure 1.4: GDNF family interactions with GFRα receptors.................................45
Figure 1.5: NGF and proNGF’s roles in cell survival............................................46
Figure 1.6: Processing of the DNSPs..................................................................47
Figure 1.7: Role of GAPDH in mediating apoptosis.............................................48
FIgure 3.1: Physical characterization of the DNSPs............................................68
Figure 3.2: The CD analysis of the stability of the DNSPs in vitro.......................70
Figure 3.3: Heparin affinity chromatography of the DNSPs and GDNF...............71
Figure 3.4: Protective effects of the DNSPs........................................................72
Figure 4.1: Protective effects of DNSP-11 and GDNF against 6-OHDA..............98
Figure 4.2: DNSP-11 does not bind to GFRα1....................................................99
Figure 4.3: Effects of DNSP-11 on GDNF mRNA levels....................................100
Figure 4.4: Effects of DNSP-11 on GDNF protein levels....................................101
Figure 4.5: Proteomic pull down with biotinylated DNSP-11..............................102
Figure 4.6: Potential binding partners for DNSP-11...........................................103
Figure 4.7: DNSP-11’s interaction with GAPDH................................................105
Figure 4.8: Effect of GAPDH nitrosylation on DNSP-11 binding........................106
Figure 4.9: Nitrosylation of GAPDH with varying GSNO concentrations...........107
Figure 4.10: Effects of DNSP-11 on nuclear GAPDH levels in MN9D cells.......108
Figure 4.11: Effects of DNSP-11 on nuclear GAPDH levels in HEK293 cells....109
Figure 4.12: Effects of DNSP-11 on nuclear GAPDH levels in HEK293 cells....110
Figure 4.13: Effects of DNSP-11 on nuclear GAPDH levels after 5 minute 
treatment in MN9D cells.....................................................................................111
Figure 4.14: Changes in nuclear GAPDH levels in MN9D cells.........................112
ix
Chapter One: Introduction
I. Overview
This chapter provides background information on Parkinson’s disease 
(PD) including its history, pathophysiology, and etiology.  This includes 
information about the genetic and environment influences on PD.  Details about 
the current treatment for PD are also presented here.  These current therapies 
function to treat the symptoms of PD, but do not stop the loss of dopaminergic 
neurons associated with PD.  Investigations of neurotrophic factors, such as glial 
cell-line derived neurotrophic factor (GDNF), for the treatment of PD are also 
discussed here including the observed challenges associated with large molecule 
therapies.  Due to these challenges, we have introduced a group of three small 
peptides derived from the pro- and mature sequence of GDNF as potential 
therapeutic molecules.  The chemical characteristics of these peptides, as well as 
their protective effects, are evaluated and discussed here. 
II. Introduction to Parkinson’s disease
a. Background/History
Though symptoms of PD have been observed and recorded in writings 
and artwork since ancient times, such as in AD 175 when Galan described what 
he referred to as shaking palsy in his writings, it wasn’t until 1817 when James 
Parkinson published “An Essay on the Shaking Palsy” (Parkinson, 2002) that 
Parkinson’s Disease was first recognized as a medical condition (Figure 1.1). 
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The essay was based on six patients that Parkinson had observed in his practice 
and on the streets of the surrounding area.  Sixty years after the publication of 
Parkinson’s essay, Jean Martin Charcot began studying PD, recognized the 
importance of James Parkinson’s work and named the condition after him, but it 
was not until the 1960s that the pathology of PD became well understood.
PD is associated with a characteristic set of motor symptoms.  In order for 
PD to be diagnosed, the patient must have bradykinesia coupled with at least 
one of four other symptoms that include resting tremor, gait difficulty, postural 
instability, and rigidity (Hardy et al., 2006).  PD was initially classified as a motor 
disorder; however, it is becoming clear that a number of non-motor symptoms 
accompany PD and that there are a variety of autonomic symptoms associated 
with the disease, the most common of which is constipation.  As the disease 
progresses, it is common for symptoms such as anxiety, depression, and 
eventually dementia to develop. 
Currently affecting approximately one and a half million Americans with 
sixty thousand new cases diagnosed each year (Parkinson’s Disease 
Foundation, 2013), Parkinson’s disease is the second most common 
neurodegenerative disease.  These numbers represent a significant financial 
impact on the patients and their families as well as on society as a whole.  
Currently, PD costs America twenty-five billion dollars each year (Parkinson’s 
Disease Foundation, 2013).  This accounts for costs associated with treatment 
and medical care and social security payments, as well as the lost productivity, 
lost wages of the patients suffering from PD, and the cost to caregivers.  The 
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individual cost of treatment for PD is also significant.  Medications for treatment 
of the disease cost approximately twenty-five hundred dollars each year with the 
additional costs of up to one hundred thousand dollars for surgical therapeutic 
options (Parkinson’s Disease Foundation, 2013). 
b. Pathophysiology
i. Loss of dopaminergic neurons
PD pathology is characterized by a loss of dopaminergic neurons in the 
basal ganglia, specifically the substantia nigra pars compacta region of the 
midbrain.  The neurons within the substantia nigra pars compacta communicate 
with the striatum also found in the basal ganglia.  The loss of dopaminergic 
neurons in the substantia nigra results in an overall reduction in the amount of 
dopamine that is released in the striatum (Figure 1.2).  As a result, a lack of 
communication is caused between the basal ganglia and the motor cortex, which 
leads to a loss of motor control. 
ii. Lewy body formation
Another characteristic of PD is the presence of Lewy bodies in the brain. 
Lewy bodies are intracellular inclusions containing α-synuclein.  While α-
synuclein’s physiological function is currently unknown, in pathological 
conditions, α-synuclein has been observed as a major component of intracellular 
inclusion bodies common in several neurodegenerative diseases (Alim et al., 
2004).  They are toxic to dopaminergic neurons and have been widely associated 
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with the death of dopaminergic neurons that is observed in PD.  Though there is 
a loss of dopaminergic neurons in the substantia nigra, Lewy body formation 
does not appear initially in this area of the brain.  Braak staging of PD describes 
how Lewy bodies first appear in regions of the brain other than the substantia 
nigra, such as the olfactory bulb, and then progress through the brain and 
eventually reach the substantia nigra at which point motor symptoms become 
apparent (Braak et al., 2002; 2003). 
Lewy body formation is a hallmark of all PD cases.  However, in cases of 
parkinsonism, a condition characterized by motor symptoms similar to PD, Lewy 
body formation is not necessarily observed but, when present, they are primarily 
found only within the substantia nigra rather than throughout the brain as they 
are in PD.  Similarly to PD, however, parkinsonism symptoms can also be treated 
by the replacement of dopamine in the brain (Hardy et al., 2006).
iii. Other deficits
While the loss of dopaminergic neurons is primarily responsible for the 
symptoms of PD, there is widespread neuron loss in the central nervous system, 
including the locus ceruleus (LC) (Greenfield and Bosanquet, 1953; Chan-Palay 
and Asan, 1989; Forno, 1996) and the nucleus basalis of Meynert (NBM) (Arendt 
et al., 1983; Gaspar and Gray, 1984; Nakano and Hirano, 1984).  Data from 
recent studies looking at genetic and environmental causes of PD have revealed 
the role of mitochondrial dysfunction in the disease (Greenamyre et al., 2001; 
Dawson and Dawson, 2003; Castello et al., 2007; Mortiboys et al., 2007; Gash et 
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al., 2008; Bueler, 2009).  Additionally, it has been observed that sporadic cases 
of PD are associated with a decrease in mitochondrial complex I activity. 
c. Etiology
PD currently affects one and a half million people in the United States with 
50-60,000 new cases diagnosed each year (parkinson.org).  Age is the largest 
risk factor for PD with the onset of idiopathic PD occurring between 55 and 80 
years old (Tanner, 1992).  PD is most commonly thought to be the result of a 
combination of factors, including genetic and environmental influences (Thomas, 
2009).  It currently affects 1% of the over 65 population (Tanner, 1992).  While 
familial forms of PD are less common and only account for 5-10% of all cases, 
the onset of disease with familial PD is earlier, usually less than 45 years of age 
(Dawson and Dawson, 2003; Bueler, 2009).  Despite all of the work that has 
been done in the field, the etiology is still not well understood. 
i. Genetics
There is evidence from epidemiologic studies that PD has a genetic 
component.  One study showed that residents in the general population in New 
Jersey had a 2% chance of having PD at the age of eighty (Lazzarini et al., 
1994).  However, if the patient had a parent or sibling with PD, their chance of 
getting PD increased to 5-6%, and if the patient had a parent and sibling 
suffering from PD then their probability of having PD increased to between 
20-40% (Lazzarini et al., 1994).  Even though PD has been shown to have a 
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genetic link, the majority of PD cases are sporadic with less than 10% of the 
cases resulting from strictly genetic causes (Thomas and Beal, 2007; Bueler, 
2009).  One distinction between the two forms of PD is that familial PD cases 
typically have an earlier onset of symptoms than sporadic cases.  
Familial PD has been shown to result from mutations in six genes, 
including α-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2), parkin 
(PRKN), DJ1, PTEN-induced putative kinas (PINK1), and ATPase type 13A2 
(ATP13A2) (Table 1.1) (Bekris et al., 2010).  The genes associated with PD 
exhibit both autosomal dominant inheritance (SCNA, LRRK2) and autosomal 
recessive inheritance (PARK2, DJ1, PINK1, ATP13A2).  Variations in additional 
genes, such as MAPT, LRRK2, and GBA, have been shown to be risk factors 
and increase susceptibility for PD (Bekris et al., 2010).  While all of these 
mutations result in some form of PD, there are differences between the resulting 
disease characteristics depending on the gene mutation that is responsible.  
Increased levels of expression of SNCA (PARK1/PARK4) have been 
observed in presynaptic nerve terminals all through the mammalian brain 
(George, 2002).  The protein is typically found in an unfolded form that can take 
on both monomeric and oligomeric conformations (Uversky, 2003) and is 
associated with Lewy bodies (Spillantini et al., 1997).  Mutations in SNCA 
(autosomal dominant) are often associated with an increase in self-aggregation 
and oligomerization of the protein (Conway et al., 1998; Pandey et al., 2006) and 
the resulting form of PD that occurs typically has an early onset and progresses 
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quickly (Bekris et al., 2010).  This form of PD is also accompanied by a few 
atypical symptoms, including myclonus and hypoventilation (Bekris et al., 2010). 
LRRK2 is expressed in numerous body regions, including the central 
nervous system (CNS), heart, kidney, lung, liver, and peripheral leukocytes 
(Zimpich et al., 2004; Paisan-Ruiz et al., 2004).  Within these regions, the protein 
can be located in a variety of different cellular areas, such as the cytosol, 
mitochondrial outer membrane, plasma membrane, lysosomes, endosomes, 
transport vesicles, Golgi apparatus, synaptic vesicles, and lipid rafts (West et al., 
2005; Biskup et al., 2006; Hatano et al., 2007).  While it is known that mutations 
in LRRK2 result in PD, the normal function of the protein is not well understood; 
although, the protein has been identified as a tyrosine kinase-like protein (Mata 
et al., 2006) and has been shown to be involved in protein-protein interactions 
(Zimprich et al., 2004).  Mutations in LRRK2 (autosomal dominant) are different 
from mutations in SNCA in that these mutations result in a PD that typically has a 
later onset and does not result in dementia (Zimprich et al., 2004); this form of 
PD has been shown to result in cell loss and Lewy body formation in the 
substantia nigra, along with limited Lewy body formation in the cortex (Khan et 
al., 2005).
PRKN is a member of the “ring between ring finger” family of E3 ubiquitin 
ligases that is found within the cytosol, synaptic vesicles, Golgi complex, 
endoplasmic reticulum, and the mitochondrial outer membrane (Shimura et al., 
2000; Kubo et al., 2001; Darios et al., 2003: von Coelln et al., 2004; Mouatt-
Prigent et al., 2004).  Mutations in PRKN result in alterations in the protein’s 
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solubility, localization, and its ability to form aggregations (Cookson et al., 2003; 
Gu et al., 2003; Wang et al., 2005).  These mutations (autosomal recessive) 
result in early onset PD, with the typical onset being between childhood and 40 
years of age (Lucking et al., 2000), and are accompanied by dystonia.  
Characteristics of this form of PD include gliosis and cell loss in the substantia 
nigra; however, there are typically no Lewy bodies formed and less involvement 
of the locus coeruleus (Takahashi et al., 1994; Mori et al., 1998).  Additionally, 
this form of PD is responsive to levodopa. 
DJ1 is a member of the peptidase C56 family of proteins and it forms a 
homodimer (Moore et al., 2003).  It is expressed throughout the body, including 
the brain, (Bandopadhyay et al., 2004) but is primarily found within the cytosol, 
and can also be located within the mitochondria (Zhang et al., 2005). PD that 
results from mutations in DJ1 (autosomal recessive) is rare and, therefore, there 
is little clinical information about the resulting disease.  The onset of this form of 
PD is typically between the ages of 20 and 40 (Bonifati et al., 2003).  However, it 
has been reported that these patients also suffer from psychiatric symptoms, 
short stature, and brachydactyly (Dekker et al., 2003; 2004).  
PINK1’s function is unknown; however, it is known that it contains a serine/
threonine protein kinase domain (Valente et al., 2001) and there is evidence that 
it is involved in neuroprotection against mitochondrial dysfunction and 
proteasome-induced apoptosis (Valente et al., 2001; Valente et al., 2004; Akundi 
et al., 2012).  It is expressed in the brain and systemic organs, and locates to the 
mitochondrial matrix and the intermembrane space (Silvestri et al., 2005).  PINK1 
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(autosomal recessive) mutations result in an early onset form of PD (fourth to fifth 
decade of life); however, this form of PD progresses more like late onset PD in 
that it progresses slowly.  This form of PD responds well to levodopa and is often 
associated with dementia (Valente et al., 2001; Hatano et al., 2004; Bonifati et 
al., 2005; Tan et al., 2006).  
ATP13A2 is a lysosomal membrane protein that is a member of the P5 
subfamily of ATPases (Ramirez et al., 2006).  It is expressed in the brain, mostly 
in the ventral midbrain (Ramirez et al., 2006).  Mutations in ATP13A2I (autosomal 
recessive) results in an atypical form of PD known as Kufor-Rakeb syndrome, a 
disease characterized by early onset symptoms (11-16 years old).  It is 
responsive to levedopa and its symptoms include dementia and supranuclear 
gaze palsy (Najim al-Din et al., 1994; Williams et al., 2005).
Identification of the genetic mutations that are linked to familial forms of 
PD helps to better understand the mechanisms that are involved in the 
development of the disease.  Some of the genes that have been identified have 
shown evidence that damage to the mitochondria is a contributing factor to PD 
progression (Valente et al., 2001; Valente et al., 2004; Silvestri et al., 2005; 
Zhang et al., 2005).  However, even with this evidence, the exact mechanism that 
is responsible for the development and progression of PD is still unclear.
ii. Environmental
While there has been a genetic component identified in the development 
of PD, there are still only approximately 20% of patients that have a family history 
9
of the disease.  This indicates that a large number of cases result from some 
other cause, such as environmental factors (Bonifati et al., 1995).  Recent 
studies have shown that there are links between environmental toxins and 
incidents of PD.  Studies that have looked at regional differences in PD rates 
demonstrate that environmental toxins may be a contributing factor in the 
development of the disease.  Increases in PD rates in rural communities suggest 
that toxins such as pesticides and herbicides could increase the risk of 
developing PD (Koller et al., 1990; Granieri et al., 1991; Svenson et al., 1993; 
Hubble et al., 1993), while higher incidences of PD in industrialized, urban areas 
imply that byproducts of industrialization may be linked to PD (Aquilonius and 
Hartvig, 1986; Schoenberg et al., 1988; Rybicki et al., 1993).  However, not all 
studies agree on the observed increase in PD in rural and industrial, urban areas. 
PD has been linked to exposure to pesticides (Costello et al., 2009; 
Dhillon et al., 2008; Gorell et al., 1998; Menegon et al., 1998), heavy metals, and 
organic pollutants.  One example of a solvent that has been linked to the 
development of PD is trichloroethylene (TCE).  Patients that have undergone 
long term TCE exposure have been linked to cases of PD and Parkinsonism 
(Gash et al., 2008).  A study evaluating twins who were exposed to several 
different solvents has also shown that exposure to TCE significantly increased 
the risk for developing PD.  Other solvents such as perchloroethylene (PERC) 
and carbon tetrachloride (CCl4) were associated with an increased risk of 
developing PD (Goldman et al., 2012).  Because environmental toxins have 
been shown to contribute to the causes of PD, toxins such as 1-methyl-4-
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phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat are all 
commonly used to induce animal models of PD.  These toxins provide valuable 
information about the mechanisms that underlie the neuropathology of PD.  
Currently, it is thought that these toxins, like TCE, induce mitochondrial 
dysfunction and cause oxidative stress, damaging dopaminergic neurons 
(Greenamyre et al., 2001; Castello et al., 2007; Mortiboys et al., 2007; Gash et 
al., 2008).
MPTP has been shown to induce PD-like symptoms in rodents, primates, 
and humans through its selective neurotoxic effects on dopaminergic neurons 
(Langston et al., 1984; Ballard et al., 1985).  MPTP-induced toxicity is primarily 
an outcome of impairment in mitochondrial respiration (Nicklas et al., 1985; 
Przedborski and Jackson-Lewis, 1998; Przedborski et al., 2000) as a result of 
MPP+, the toxic metabolite, being taken up by nigrostriatal neurons (Chiba et al., 
1984).  The observed impairment in mitochondrial respiration has been shown to 
be a result of inhibition of mitochondrial complexes I, III, and IV (Desai et al., 
1996).
Rotenone, a commonly used pesticide and piscicide, has been shown to 
inhibit mitochondrial complex I in nigrostriatal dopaminergic neurons (Betaret et 
al., 2000; Amberg et al., 2012).  The primary cause of damage to mitochondrial 
complexes I and II by rotenone is an increase in reactive oxygen species (ROS) 
(Panov et al., 2005).  It has also been shown that the result of complex I 
inhibition as a result of chronic rotenone exposure results in an increase in 
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aggregation of α-synuclein and ubiquitin, which results in oxidative damage and 
caspase dependent death (Sherer et al., 2002).
Paraquat is a commonly used herbicide that has structural similarities to 
MPTP, although it does not appear to work through the same mechanism.  The 
mechanism by which paraquat induces parkinsonism is not well understood.  
There is, however, evidence that paraquat causes some weak inhibition of 
mitochondrial complex I, in contrast to both MPTP and rotenone which have 
strong mitochondrial complex I inhibitory properties (Richardson et al., 2005).  In 
addition, there is evidence that exposure to paraquat can cause lipid peroxidation 
that results in damage to dopaminergic neurons (Dinis-Oliveira et al., 2006).
Data about regional differences in the frequency of PD have provided 
evidence that suggests exposure to environmental toxins likely result in an 
increased risk of developing PD (Racette, 2012).  While there are studies 
showing these regional differences correlating with increased incidences in both 
rural (Koller et al., 1990; Granieri et al., 1991; Svenson et al., 1993; Hubble et al., 
1993) and industrial, urban areas (Aquilonius et al., 1986; Schoenberg et al., 
1988; Rybicki et al., 1993), there are also studies that refute these differences.  
Many of the inconsistencies in these studies result from limited sample sizes 
being available (Racette, 2012).  Therefore, methods to improve sample size and 
evaluate the dose response data are necessary to better understand the role of 
environmental toxins in the development of PD.  
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iii. Excitotoxicity
Excitotoxicity is suspected as one of the causative factors resulting in the 
death of dopaminergic neurons observed in PD (Levy et al., 2009).  Evidence 
indicates that changes in glutamate, the major excitatory neurotransmitter in the 
central nervous system, regulation can have significant impact on neurons 
(Olney, 1990).  It is believed that excitotoxicity can damage neurons directly via 
overstimulation of NMDA receptors; however, in PD it is indicated that damage as  
a result of excitotoxicity follows an indirect route (Albin and Greenamyre, 1992; 
Greene and Greenamyre, 1996).
iv. Inflammation
Inflammation plays a role in many neurodegenerative diseases, including 
PD.  The immune response most commonly associated with neurodegenerative 
disease is the activation of microglia (Kreutzberg, 1996).  It has been shown that 
levels of proinflammatory cytokines, such as tumor necrosis factor-α and 
interferon-γ, are up regulated in the brain after exposure to toxins that have been 
linked to PD (Litteljohn et al., 2010).  This increase in cytokines then results in a 
loss of dopaminergic neurons.
In addition to inflammation in the CNS, there is also evidence that 
systemic inflammation can exacerbate the neuronal loss in PD.  It has been 
observed that cytokine mRNA are increased in the microglia during animal 
models of PD while protein levels such as IL-1β do not increase (Depino et al., 
2003).  This has given rise to the theory of “primed microglia,” that can be 
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“activated” after a secondary peripheral proinflammatory stimulus.  Once these 
primed microglia become activated, they continue to contribute to neurotoxicity 
by producing free radicals and cytokines. 
d. Treatments
Current PD treatments (Table 1.2) function by treating the symptoms but 
do not actually reverse the cell loss that is responsible for causing the symptoms.  
During the initial treatment (less than five years), PD symptoms can be greatly 
reduced and quality of life improved.  However, as time passes, all of the 
treatments become less effective and the symptoms return (Mayo Clinic, 2012).  
i. Symptomatic treatments
Levodopa is the current gold standard of treatment for PD symptoms.  It is 
a naturally occurring precursor for dopamine that can be taken orally because, 
unlike dopamine, levodopa can cross the blood brain barrier.  After levodopa is 
taken, it is transported across the blood brain barrier to the brain where it is 
converted into dopamine by DOPA decarboxylase, or L-amino acid 
decarboxylase in striatal dopaminergic neuron terminals (Figure 1.3) (Lopez et 
al., 2001).  In the drug Sinement, levodopa is combined with carbidopa, which 
helps to prevent the conversion of levodopa to dopamine outside of the brain.  
One of the most noticeable side effects of levodopa treatment is the appearance 
of dyskinesia, which affects the patient’s voluntary movement.  Lowering the 
dose of levodopa can reduce dyskinesia, but will also reduce the level of 
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effectiveness in treating the PD symptoms.   Further, as levodopa treatment 
continues, it tends to exhibit a “wearing off” effect and loses its effectiveness as 
the disease progresses.
Another class of PD treatments includes dopamine receptor agonists.  
These therapies do not increase the amount of dopamine present in the brain, 
but instead, act to mimic the presence of dopamine, by interacting with the 
dopamine receptors present in the brain (Figure 1.3). Most of the currently 
available dopamine agonists on the market interact with the D2 receptor, although 
there is cross talk with other dopamine receptors (Table 1.3).  Dopamine agonists 
were introduced for the treatment of PD in the late 1970s (Factor, 1999) and 
were initially used as a combination therapy with levodopa.  However, it has been 
observed that dopamine agonists offer beneficial effects at all stages of PD both 
when given in conjunction with levodopa and as a monotherapy.  When given 
with levodopa, dopamine agonists can delay levodopa-induced motor 
complications (Jankovic and Stacy, 2007).
MAO-B is an enzyme found in the outer mitochondrial membrane that is 
responsible for metabolizing dopamine in the brain.  Therefore, if the levels of 
MAO-B in the brain are reduced or MAO-B is rendered inactive, dopamine levels 
in the brain would remain elevated.  MAO-B inhibitors, such as Selegiline 
(Deprenyl), function by inhibiting the breakdown of endogenous dopamine, as 
well as that produced as a result of levodopa treatment, resulting in an overall 
increase in the total amount of dopamine available in the brain (Figure 1.3). 
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There are a few other treatments that can be used but that are less 
common because they are not as effective and the side effects associated with 
the treatment are more severe.  Catechol O-methyltransferase (COMT) inhibitors 
function by inhibiting the breakdown of levodopa (Figure 1.3).  They can be used 
in combination with levodopa therapy.  However, they have been associated with 
liver damage and are therefore only used in patients that are not responding to 
other treatment options. 
Anticholinergics can be used to reduce PD associated tremors.  However, 
these drugs offer modest effects and are often associated with significant side 
effects. NMDA blockers can be prescribed to treat the early symptoms of PD.  
They are often used later to supplement levodopa treatment to help alleviate 
dyskinesia side effects.
ii. Physical therapy and surgical treatments
Physical therapy can be used to help combat the symptoms of PD.  While 
these exercises cannot stop the disease from progressing, the muscle 
maintenance can help to counteract some of the effects of the disease. 
Deep brain stimulation is a surgery that can be performed on patients with 
advanced PD.  During this surgery, electrodes are implanted in the brain.  These 
electrodes can deliver current to the brain to help reduce the symptoms of PD.  
This treatment option is primarily used for patients who are no longer responding 
to other therapies, such as levodopa.  It can also be used to eliminate some of 
the dyskinesia that is associated with levodopa. 
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iii. Growth factors
Attempts to target the source of PD and not just treat the symptoms have 
been undertaken.  Based on their endogenous role, neurotrophic factors are one 
class of molecules that have been evaluated for their potential to treat PD.  
Neurotrophic factors are a class of functionally related proteins that play a key 
role in neurite formation and growth during development and after injury (Ibáñez, 
1998).  Because of their native cellular function, neurotrophic factors have 
received considerable attention as potential therapeutic agents for 
neurodegenerative disorders, including PD.
1. Role of growth factors in the treatment of neurodegenerative diseases
The first neurotrophic factor described was nerve growth factor (NGF) 
(Levi-Montalcini and Hamburger, 1951).  Studies have shown that NGF levels are 
decreased in PD patients and animal models (Lorigados et al., 1992, 1996).  
Therefore, it is a reasonable choice for use as a potential treatment of PD.  
Studies have shown that in rodent models of PD, NGF can increase the survival 
of grafted adrenal chromaffin cells which results in an increase in the functionality 
of the treatment (Date et al., 1997; Silani et al., 1990).  However, this work has 
not translated with consistent results into primate models and clinical trials 
(Hurtig et al., 1989; Peterson et al., 1989; Olson et al, 1990). 
The function of brain-derived neurotrophic factor (BDNF) is to promote the 
survival and differentiation of cholinergic neurons (Alterson et al., 1990; Knusel et 
al., 1991) and has been shown to play a role in neurogenesis (Benraiss et al., 
17
2001; Zigova et al., 1998).  Similar to NGF, levels of BDNF have been shown to 
be reduced in PD patient’s brains (Howells et al., 2000, Mogi et al., 1999).  BDNF 
has been shown to effect dopaminergic neurons in culture (Feng et al., 1999; 
Hyman et al., 1991; Yoshimoto et al., 1995) and in whole tissue after both 6-
OHDA and MPTP exposure (Hung and Lee, 1996; Levivier et al., 1995).  BDNF 
has also been shown to reverse behavioral and neurochemical deficits when 
administered to the substantia nigra before and after nigrostriatal injury (Altar et 
al., 1992).
Neurotrophin-3 (NT-3), also known as neurotensin, and neurotrophin-4/5 
(NT-4/5) are also members of the neurotrophin family.  Like the other 
neurotrophins, NT-3 promotes survival and differentiation of neurons.  It primarily 
functions through the TrkC receptor (Lamballe et al., 1991; Tessarollo et al., 
1993); however, it interacts with the TrkB receptor to a lesser extent. NT-3 has 
been shown to protect dopaminergic neurons (Gu et al., 2009).  Additionally, 
NT-4/5 has been shown to have protective effects on a variety of different types 
of neurons, including dopaminergic neurons (Hyman et al., 1991, 1994). 
The glial cell-line derived neurotrophic factor (GDNF) family of proteins, 
which includes GDNF, neurturin, artemin and persephin, is a small subfamily of 
the transforming growth factor beta (TGF-β) superfamily (Krieglstein et al., 1995; 
Baloh et al., 1998; Milbrandt et al., 1998). The GDNF family of proteins have 
been shown to play key roles in numerous cell processes, including cell survival, 
neurite outgrowth, cell differentiation, and cell migration.  These functions are 
carried out through their ability to specifically activate RET tyrosine kinase 
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pathways.  Due to their unique role, this family of trophic factors has been 
evaluated as potential candidates for neurodegenerative disorder treatment.
GDNF is a 33-45 kDa protein that interacts with a multi-subunit receptor 
system that consists of GDNF family receptors alpha-1 (GFRα1) and RET 
(Figure 1.4).  Interaction with these receptors can initiate a variety of intracellular 
pathways, including Ras-MAPK (Worby et al., 1996), PLCγ-dependent pathway 
(Borello et al., 1996), phosphoinositol 3-kinase (PI3-K), and Jun N-terminal 
kinase (JNK) (Van Weering and Bos, 1998).  The second member of the GDNF 
family of proteins is neurturin (NTN).  NTN is 12 kDa that has been shown to 
support the survival of sympathetic neurons (Kotzbauer et al., 1996).  Like GDNF, 
NTN interacts with the RET receptor, but it can interact with GFRα1 and GFRα2 
receptors (Figure 1.4) to induce activation of the MAP-K and PI3K pathways and 
promote survival of dopaminergic neurons (Creedon et al., 1997).  It has been 
observed that both GDNF and NTN can interact with GFRα1 and GFRα2 (Figure 
1.4); however, GDNF preferentially interacts with GFRα1, while NTN is more 
likely to interact with GFRα2 (Figure 1.4) (Sanicola et al., 1997; Klein et al., 
1997).  Artemin (ARTN) interacts primarily with GFRα3, although there is some 
crosstalk with GFRα1 (Airaksinen et al., 1999).  Persephin (PSPN) only interacts 
with GFRα4 and RET and does not crosstalk with any of the other GDNF family 
receptors (Figure 1.4) (Lindahl et al., 2000).  GFRα4 is unique in that, when 
compared to the other GDNF family receptors, it does not contain the first N-
terminal Cys-rich domain.
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NTN, a GDNF family member, has a 40% sequence similarity to GDNF 
and has shown promise as a PD therapeutic.  Ceregene Inc. developed 
CERE-120, a recombinant AAV2- based vector that encodes NTN.  CERE-120 
has been shown to result in rapid (within four weeks) and long lasting (up to one 
year) expression of NTN (Gasmi et al., 2007b).  AAV2-NTN has been shown to 
protect neurons from 6-OHDA in rats (Gasmi et al., 2007a).  Additionally, AAV2-
NTN was shown to increase TH+ neurons in aged monkeys (Herzog et al., 2007) 
and protect in MPTP- lesion monkeys (Kordower et al., 2006).  Based on the 
success of CERE-120 in animal models, it was moved into phase I clinical trials.  
During the phase I clinical trials, beneficial effects, such as a 40% reduction in 
UPDRS-motor “off” scores, a substantial increase in “on” time without 
dyskinesias, a reduction in “total off time” and improvement on timed motor tasks, 
were observed without any significant adverse reactions being reported (Marks et 
al., 2008).  CERE-120 then moved into phase II clinical trials.  However, this trial 
did not show any significant beneficial results (Bartus, 2012).  This was likely due 
to the difficulties associated with the delivery of the molecule to the brain.
2. Glial cell line-derived neurotrophic factor
GDNF, the most promising neurotrophic factor for the treatment of PD to 
date, has been shown to increase the survival of cultured dopaminergic neurons, 
which lead to further investigation in connection with PD (Lin et al., 1993).  In 
addition, in vivo GDNF has been shown to protect and restore neurons after 
cytotoxic insults (Hoffer et al., 1994; Tomac et al., 1995; Gash et al., 1996; 
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Herbert and Gerhardt, 1997; Cass et al., 1999).  GDNF has also shown promise 
extensively as a therapeutic by increasing dopamine levels in the substantia 
nigra, improving motor deficits and exhibiting long-lasting effects in aged 
primates and PD patients (Salvatore et al., 2004).  Unfortunately, the therapeutic 
development of GDNF has been discontinued because of the reported presence 
of GDNF antibodies in clinical trials, unpublished data indicating cerebellar 
toxicity at high concentrations in primates, and patent protection issues (Gill et 
al., 2006; Slevin et al., 2005; Lang et al., 2006).   
Like all neurotrophic factors, GDNF is initially produced as a 221 amino 
acid inactive precursor protein that is cleaved to produce a 134 amino acid 
mature protein (Lin et al., 1993).  The mature form of GDNF is a glycosylated 
homodimer that is approximately 33-45 kDa, with the monomer being 
approximately 16 kDa (Lin et al., 1994).  While the cellular function of the mature, 
processed GDNF protein is known, the role of the highly conserved proprotein 
sequence is not fully understood.
Numerous studies have shown GDNF to have promise as a potential 
therapeutic for PD.  In addition to being able to enhance the growth and survival 
of unstressed neurons (Lin et al. 1993), GDNF has also been shown to protect 
against toxins in vitro, such as 1-methyl-4-phenylpyridinium ion (MPP+) (Hou et 
al.,1996).  Further benefits of GDNF have been observed in rodent models; the 
administration of GDNF to the substantia nigra prior to treatment with the toxin 6-
hydroxydopamine (6-OHDA) results in a significant protection of dopaminergic 
neurons (Kearns and Gash, 1995; Kearns et al., 1997; Fox et al., 2001).  This 
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neuronal protection is also associated with an observed protection from the 
reduction in evoked dopamine release that is typically associated with 6-OHDA 
treatment (Cass and Manning, 1999).   Based on the data from the rodent 
models, studies in which GDNF was administered to non-human primates were 
carried out.  Again, increases in dopamine levels (Gash et al., 1995; Grondin et 
al., 2002) and improvement in PD related behaviors were observed in MPTP 
primate models (Gash et al., 1996; Zhang et al., 1997).
3. Clinical trials of GDNF
Based on the data from rodent and non-human primate studies, GDNF 
was moved into phase I clinical trials.  The initial trials were open-label trials 
carried out in Bristol, UK and at the University of Kentucky, Lexington, KY.  These 
studies used a programmable pump (Medtronic) and catheters system for the 
delivery of GDNF (Gill et al., 2003; Slevin et al., 2005).  In both of these clinical 
trials a significant improvement in the Unified Parkinson’s Disease Rating Scale 
(UPDRS) was observed (Gill et al., 2003; Slevin et al., 2005).
However, despite the initial promise of the GDNF studies, it has failed to 
advance beyond phase II clinical trials. The phase II clinical trials failed to meet 
the criteria set out for significant improvement in the patients that was required 
for the studies to continue (Lang et al., 2006; Sherer et al., 2006).  Complications 
associated with the delivery of a large protein to the brain are believed to have 
contributed to the failure of GDNF in clinical trials (Gill et al., 2003; Slevin et al., 
2005; Lang et al., 2006).  The delivery catheter and the distribution of GDNF 
22
varied during the clinical trials and may have contributed to the appearance of 
auto-antibodies, as well as the lack of significant improvements in the patients 
that were treated (Gill et al., 2003; Slevin et al., 2005; Lang et al., 2006). 
III. Challenges of growth factors
The development of growth factors as PD therapeutics faces several 
difficulties that must be overcome. The major obstacle is delivering a large 
molecule, such as GDNF (33-45 kDa), to the brain because they cannot cross 
the blood brain barrier.  This has resulted in the use of invasive delivery 
techniques, such as CED through a surgically implanted catheter, to target 
administration of growth factors.  These treatments require surgical procedures, 
which are limited by several factors including training qualified surgeons and 
having adequate space to perform the procedure.  In addition, growth factors can 
be challenging to synthesis for use in a therapeutic agent.  One possible solution 
to address and help eliminate these problems is to develop small molecules, 
which possess neurotrophic-like properties and can be modified for systemic 
deliver, as an alternative therapeutic.
a. Large size-difficult to deliver
In order to treat PD, it is necessary to deliver the drug to the affected area 
of the brain. However, it is difficult to deliver large molecules to the brain through 
systemic methods because these molecules cannot cross the blood brain barrier. 
In order to circumvent this problem, direct delivery of the molecule to the affected 
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brain region was required. In the case of the GDNF clinical trials, this was 
achieved by implanting a pump in the abdomen that could hold a one-month 
supply of the drug. This pump was connected via tubing to the brain so that 
GDNF could be directly delivered by convection enhanced delivery (CED) (Yin et 
al., 2011; Taylor et al., 2013). However, this requires an intracranial surgical 
procedure for implantation and monitoring of the device. 
b. Delivery methods
When considering delivering GDNF to the CNS, it is important to note that 
GDNF receptors are found throughout the nervous system meaning that delivery 
to specific regions could be essential for reducing any off target effects. It has 
been shown that GDNF distribution to the target tissues correlates with the 
observed effects on midbrain dopamine neurons and improvement in motor 
function (Gash et al., 2005). In order to overcome the problems associated with 
delivering large molecules to the brain, a variety of different techniques have 
been developed. These include delivering the growth factors by convection 
enhanced delivery (CED), which can increase the distribution of the drug within 
the brain. Also, other delivery methods are being tested; these include using viral 
vectors to deliver the growth factors to the brain. 
i. Convection enhanced delivery
Convection enhanced delivery (CED) is a technique used to deliver 
molecules to solid tissue by using a bulk flow infusion system.  CED allows 
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clinically relevant volumes of molecules to be distributed to clinically relevant 
tissues (Bobo et al., 1994; Morrison et al., 1994).  The use of bulk flow in CED 
offers several advantages, such as allowing for a greater distribution volume than 
simple diffusion (Bobo et al., 1994).  Further, a more uniform distribution of the 
molecule that is being delivered within the target region is made possible with 
CED, which also allows the entire molecule is able to be delivered to the target 
region (Morrison et al., 1994).  This helps to cut down on the dose required for 
the maximum effect (Morrison et al., 1994).
This method has become widely accepted as a method for delivering 
therapeutic agents to targeted brain regions (Lonser et al., 1998; Bankiewicz et 
al., 2000; Krauze et al., 2005). While CED has been shown to be an effective 
delivery method for growth factors, including GDNF, to the brain, it is essential to 
carefully control this delivery to prevent the material from being deposited into 
undesirable locations, which can lead to adverse effects, such as the induction of 
auto-antibodies (Lang et al., 2006). In an attempt to avoid these complications, 
studies looking at co-infusion of an MRI tracer with GDNF have been conducted 
to determine the distribution of GDNF (Gimenez et al., 2011). These studies 
would allow neurosurgeons to more accurately tract the distribution of GDNF in 
the brain and monitor the delivery in real time.  This helps to reduce unwanted 
side effects associated with GDNF being delivered outside of the desired location 
in the brain as well as allowing for surgeons to know that delivery was successful 
prior to symptomatic relief.
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ii. AAV, Adenovirus, Lentivirus
Delivery of growth factors using adenoviral (Ad) vectors, adeno-associated 
viral (AAV) vectors, and lentiviral (LV) vectors have all been shown to provide 
efficient transduction in rodents, with LV also exhibiting transduction in non-
human primates (Kordower JH et al., 1999; Kordower JH et al,).
Ad vectors are capable of holding large pieces of DNA (8 kb) and can 
infect both dividing and non-dividing cells. The DNA carried by Ad vectors does 
not integrate into the host DNA so it is best used for transient expression in non-
dividing cells. While intracerebral delivery of GDNF by Ad vectors (Ad-GDNF) 
has been shown to offer protection in rats with 6-OHDA lesions (Choi-Lundberg 
et al., 1997; Choi-Lundberg et al. 1998), there has also been evidence that the 
transduced cells also express adenoviral proteins that can induce a host immune 
reaction (Wood et al., 1996; Kajiwara et al., 1997).
AAV vectors are lacking 96% of their viral genome but have the genes 
required for integrating the transgene into the host genes, thereby allowing for 
stable expression in non-dividing cells. Because the majority of the viral genome 
is absent in AAV vectors, the risk of causing a host immune response is 
diminished. However, their DNA capacity (<5 kb) is less than that of Ad vectors. 
Additionally, transgenes carried by AAV vectors exhibit a delayed expression of 
several days with full expression at about 2-3 weeks after delivery (Monahan and 
Samulski, 2000; Peel and Klein, 2000). While AAV vectors have been shown to 
be efficient for transducing neurons, they do not affect all types of neurons and 
brain regions equally because they require binding to heparin sulfate 
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proteoglycans. Treatment of 6-OHDA lesion rats with AAV-GDNF has been 
shown to rescue dopamine neuron cell bodies; however, the denervation of TH-
positive fibers in the striatum was not affected (Mandel et al., 1997; Mandel et al., 
1999).
LV vectors are developed from retroviruses, which are highly pathogenic. 
They are capable of carrying large pieces of DNA (9 kb) and can stably integrate 
into their host and exhibit long-term expression. LV-GDNF has been shown to 
induce GDNF expression in rats, mice, and monkeys (Bensadoun et al., 2000; 
Kordower and Bjorklund, 2013). In rats, this expression is similar to that seen 
with AAV-GDNF (Mandel RJ et al., 1997; Kirik et al., 2000). LV-GDNF was shown 
to increase the percentage of TH-positive neurons after lesions (Deglon et al., 
2000; Bensadoun et al., 2000).
iii. Other neurotrophic factors
Despite the evidence that BDNF can protect dopaminergic neurons, its 
large size presents difficulty when trying to deliver the molecule to the brain.  Due 
to this challenge, other delivery methods have been investigated, including in 
vivo gene transfer by adeno-associated viral vector (AAV) (Klein et al., 1999).  
Even though BDNF does show potential for protecting dopaminergic neurons, 
there has not been enough evidence to move it to clinical trials.  This is due, in 
part, to the fact that while it shows neuroprotective effects, it does not exhibit 
neurorestorative effects. 
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Additionally, mesencephalic astrocyte-derived neuorotrophic factor 
(MANF), is expressed at high levels in the hippocampus, cortex, and midbrain 
(Lindholm et al., 2008). It has been shown to promote the survival of ventral 
midbrain dopaminergic neurons (Petrova et al., 2003, 2004). It has also been 
shown to be neuroprotective and neurorestorative in 6-OHDA treated rats 
(Voutilainen et al., 2009). Conserved dopamine neurotrophic factor (CDNF) has 
also been shown to provide effects similar to MANF in 6-OHDA treated rats 
(Lindholm et al., 2007). It is thought that the activity of MANF and CDNF is 
through their protection from endoplasmic reticulum stress (Apostolou et al., 
2008; Mizobunchi et al., 2007).
Other neurotrophic factors are unlikely to overcome the problems that 
have plagued GDNF.  These alternative treatments still possess the qualities that 
have made it difficult for GDNF to move out of phase II clinical trials.  Other 
neurotrophic factors are still large and because of this, they can be complex to 
produce and face the same difficulties of delivery that affected GDNF.  Ultimately, 
the development of a smaller molecule with protective effects similar to that of 
GDNF and other neurotrophic factors would overcome these obstacles.  
IV. Biotherapeutic strategies
Neurotrophic factors, such as GDNF, possess many qualities that make 
them desirable molecules for use in treating neurodegenerative diseases, such 
as PD.  Endogenously neurotrophic factors function to support cell survival and 
growth. This function makes them good potential therapeutic candidates for 
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treating neurodegenerative disease because they are likely to be neuroprotective 
and neurorestorative. There is evidence that GDNF provides protection by 
offering mitochondrial protection and therefore mediating apoptotic pathways 
(Bradley et al., 2010; Turchan-Cholewo et al., unpublished).
Neurotrophic molecules have been attractive as drug candidates because 
of their endogenous roles of promoting cell survival. Current PD therapies, such 
as levodopa, dopamine agonists, and MAO-B inhibitors, work to alleviate the 
symptoms of PD, but do not prevent or reverse the cell loss that is the cause of 
PD. Furthermore, these treatments have side effects that commonly develop 
after repeated, long-term use.  Some of these side effects can be as debilitating 
as the symptoms of PD.  Therefore, newly developed therapies need to be 
neuroprotective (stopping cell death) and neurorestorative (promoting the growth 
of new neurons). These characteristics will allow biotherapeutic strategies to do 
more than treat the symptoms of PD; they will actually be able to stop and 
reverse the pathology. 
Damage to the mitochondria, particularly complex I of the electron 
transport chain, has been shown to play a key role in the pathology of PD.  Novel 
and more effective therapies can be developed by evaluating biotherapeutics that 
are able to provide mitochondrial protection. There is evidence that many of the 
neurotrophic molecules that have been evaluated as PD therapeutics function 
through mitochondrial protective mechanisms. 
Programmed cell death, or apoptosis, is the primary form of cell death 
observed in PD. The observed apoptosis associated with PD is primarily a result 
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of deficits in cellular respiration.  The use of therapeutics, such as neurotrophic 
molecules, that can prevent apoptosis is essential for the success of the 
treatment. 
One of the major problems associated with current biotherapeutic 
strategies for neurodegenerative diseases is the delivery of large molecules to 
the brain. Thus, a viable approach towards the development of a potential PD 
therapeutic is to construct and evaluate novel, smaller molecules with GDNF-like 
activity. These smaller molecules offer the advantage of being easier to 
synthesize and purify in addition to ultimately being simpler to modify and deliver 
to the brain by less invasive methods.
V. Peptides offer attractive molecular advantage 
Small molecules, such as peptides, offer advantages over larger 
biotherapeutic strategies. A significant advantage centers on their small size. The 
small size makes the use of peptides more realistic for non-invasive delivery to 
the brain. In addition, peptides are simpler to synthesize, modify, and purify than 
larger molecules. These peptides can then be chemically modified to allow for 
easier delivery and more effective action of the peptide. In addition, peptides are 
already used in nature as signaling peptides with a wide range of sequence 
diversity available. 
30
a. Chemical synthesis
Chemical synthesis of peptides originated in work done by Emil Fischer 
(Kent, 1988).  Following Fischer’s work, interest in peptide synthesis rose along 
with interest in the research of biologically active peptides, such as neuropeptide 
hormones and neurotransmitters.  Currently, peptides are produced by solid 
phase peptide synthesis, a process that involves the stepwise elongation of a 
peptide (Merrifield, 1963; Kent, 1988).  This procedure is almost exclusively used 
to produce peptides for research purposes (Kent, 1988).  Due to their small size, 
peptides can be more easily produced by chemical synthesis than larger, more 
complex recombinantly-produced proteins like GDNF.  For example, mature 
GDNF is a dimer that takes on a cystiene knot formation, which is more 
complicated to produce recombinantly.  In order for GDNF to be functional after it 
is recombinantly produced, it must be able to refold correctly to form its active 
confirmation.  In addition, it is necessary to be able to purify a therapeutic agent 
before it can be used.  Small peptides can be purified by relatively simple 
methods, such as high-performance liquid chromatography (HPLC).  The relative 
ease with which peptides can be produced and purified makes them attractive 
alternatives to large molecules, such as proteins, as potential therapeutics.
b. Modification
Modifying peptides either through changing the amino acid sequence or 
by chemically modifying the peptide to change their properties can help to 
improve not only their therapeutic function, but it can also allow them to be 
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delivered more easily and improve their biodistribution.  For the treatment of 
neurodegenerative diseases, such as PD, it is necessary that the molecule get 
into the affected brain region.  By modifying peptides, they can be given 
systemically or perhaps intranasally and still access the brain. Further, chemically 
modifying the peptides can alter the biodistribution of a molecule as well as alter 
the in vivo stability of the peptides.  In order to allow the peptides to have their 
desired effect after treatment, it is necessary for the peptides to be relatively 
stable once they have been delivered into the body.  A lack of in vivo stability can 
result in the peptides being quickly broken down and having a limited effect.  
Some peptides are inherently unstable in vivo and, therefore, being able to 
increase the in vivo stability of these peptides can increase the amount of time 
that they are present within the body and in doing so, they can improve the 
observed therapeutic effect.
c. Peptide signaling molecules 
 Peptides are used as biological signaling molecules.  Peptides are 
involved in numerous important roles within the body, including roles as 
neurohormones and neurotransmitters.  One example of peptides that are 
involved in a biological signaling pathway is the neuropeptide Y family, which 
includes three thirty-six amino acid peptides (neuropeptide Y, peptide YY, and 
pancreatic polypeptides).  This family of peptides interacts with G-protein-coupled 
receptors to help regulate energy balance (Nguyen et al., 2011).
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VI. Growth factor prosequences
As with many excreted proteins, growth factors are first translated as a 
preproprotein.  Processing of the growth factors during maturation results in the 
removal of the pre- and prosequences to produce the mature growth factor.  
Growth factor prosequences have long been believed to have very little, if any, 
function other than guiding the processing and folding of the mature protein. 
However, recent studies have shown that the prosequences of some growth 
factors, including NGF and BDNF, possess additional anti-apoptotic activities.  
This emerging evidence of anti-apoptotic activity suggests that growth factor 
prosequences may play a role in cell survival and maintenance that complements  
the activity of the mature growth factors that they are derived from.  
a. Roles in apoptosis
Mature NGF promotes cell survival by binding to the TrkA and p75NTR
receptors.  The p75NTR is also involved in the binding of proNGF to a heterodimer 
that consist of both this and the sortilin receptors (Figure 1.5) (Nykjaer et al., 
2004).  The recruitment of the sortilin receptor is necessary for proNGF’s ability 
to induce apoptosis (Nykjaer et al., 2004).  Brain-derived Neurotrophic factor 
(BDNF), which is also a member of the TGF-β family, is able to promote the 
survival and differentiation of neurons through the TrkB receptor tyrosine kinase.  
However, BDNF also causes low levels of cell death, which appears to be 
mediated by the p75NTR receptor (Teng et al., 2005).  
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  It has been observed that proBDNF is able to cause apoptosis at a much 
higher level than mature BDNF.  ProBDNF seems to function through the same 
mechanism as proNGF.  It is able to bind to the heterodimer of p75NTR and sortilin 
receptors, both of which are required for its apoptotic activity (Teng et al., 2005).
Studies looking at the function of proNGF have shown that the isolated 
prosequence of NGF can be used to block the induction of apoptosis (Nykjaer et 
al., 2004).  When cells expressing the sortilin and p75NTR receptors are treated 
with only the prosequence of NGF, it appears that it is able to competitively inhibit 
proNGF binding and keep sortilin from being recruited to the p75NTR receptor to 
form an active heterodimer and therefore reduce the levels of apoptosis (Nykjaer 
et al., 2004).
VII. DNSP-11
Similar to NGF and BDNF, GDNF is also produced as a proprotein. It is 
hypothesized that the GDNF prosequence functions in much the same way.  This 
would mean that some proGDNF is able to escape its normal processing and 
remain as proGDNF in the body.  This unprocessed proGDNF could be causing 
an increase in cell death.  However, when GDNF is normally processed, the 
cleaved prosequence can work to block the activity of proGDNF and increase cell 
survival by inhibiting apoptosis that would be induced by proGDNF.
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a. Processing
The GDNF presequence contains a signal sequence that targets the 
protein to the rough endoplasmic reticulum (rER), where it is processed and 
folded within the rER/Golgi complex secretory pathway.  It has long been 
believed that these prosequences were solely responsible for guiding the 
processing and folding of the mature growth factor; however, it has recently been 
shown that the prosequences of other trophic factors possess alternate apoptosis  
mediating functions compared to the mature proteins (Chao and Bothwell, 2002; 
Nykjaer et al., 2004).  This has led to the investigation of the activity of the 
prosequence of GDNF.  Evaluation of the GDNF proprotein for potential protease 
sites found internal endopeptidase sites were predicted to yield three individual 
amidated peptides of 5, 11, and 17 amino acids in length (Figure 1.6) (Immonen 
et al., 2008; Bradley et al., 2010; Kelps et al., 2011).  The rat homolog of 11, 
named BEP, amino acid sequence (DNSP-11) from GDNF’s prosequence has 
been shown to effect hippocampal neurons in a neurotropic-like manner 
(Immonen et al., 2008).  
b. Potential as a therapeutic
Preliminary evaluations of these peptides show similar functional effects 
as mature GDNF, thus making them viable candidates for further development as 
a PD therapeutic.  The peptides have been shown to increase neurite outgrowth 
in primary mesocephalic cell culture models, as well as positively affect the 
behavior in a young Fisher 344 rat model of dopaminergic dysfunction (Bradley 
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et al., 2010).  Treatment with DNSP-11 has been shown to increase basal 
dopamine (DA), dihydroxyphenylacetic acid (DOPAC), and homovanillic acid 
(HVA) in rats (Bradley et al., 2010).  While the cellular mechanism of these 
peptide sequences is unknown, these results coupled with the functional data 
from other neurotrophic factor prosequences, strongly suggest that the GDNF 
family of prosequences exhibit cellular functions. In addition, peptides offer 
advantages of a smaller size, being easier to deliver and synthesize, and less 
potential for causing an immune response than the larger mature protein. Thus, 
the propeptides require further evaluation and characterization to determine their 
functional role and potential for PD therapeutic development.  Furthermore, a 
combination of in vitro and in vivo data from a collaborative research group has 
aided in focusing our attention on DNSP-11.
By furthering our understanding of the mechanism by which DNSP-11 is 
able to provide these anti-apoptotic effects, DNSP-11’s potential as a therapeutic 
can be maximized.  This understanding also provides a foundation on which 
further studies to evaluate the functionality of DNSP-11 can be based.  Presented 
here is an evaluation of a potential mechanism that may contribute to some of 
the observed beneficial effects of DNSP-11.  This mechanism involves 
DNSP-11’s interaction with GAPDH, which is known to mediate an apoptotic 
pathway.
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c. DNSP-11 and GAPDH
The mechanism by which DNSP-11 is able to provide its observed anti-
apoptotic effects is currently not known.  One potential binding partner for 
DNSP-11 that has been identified is glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), which has previously been shown to be involved in mediating an 
apoptotic pathway (Bradley et al., 2010).  Under conditions of cell stress, GAPDH 
is nitrosylated.  Once GAPDH is nitrosylated, it is no longer metabolically active, 
resulting in two distinct pools of GAPDH existing in stressed cells.  The 
nitrosylated GAPDH can now interact with and bind to Siah-1, an E3 ubiqutin 
ligase (Hara et al., 2005).  When Siah-1 is not bound to GAPDH, it is unstable 
and so it is quickly degraded within the cell.  However, binding to nitrosylated 
GAPDH stabilizes Siah-1 and prevents it from being quickly degraded and allows 
it to have prolonged effects (Hara et al., 2005).  
GAPDH lacks a nuclear localization signal, so it normally is not located 
within the nucleus.  However, Siah-1 does possess a nuclear localization signal 
and can, therefore, move into the nucleus.  Due to the presence of a nuclear 
localization signal on Siah-1, when nitrosylated GAPDH binds to Siah-1, the 
complex is able to move into the nucleus.  Since the binding of nitrosylated 
GAPDH functions to stabilize Siah-1, it is able to degrade its nuclear targets for 
an extended period of time (Hara et al., 2005).  This leads to activation of an 
apoptotic pathway (Figure 1.7).
This pathway is of particular interest because deprenyl, a current 
therapeutic used to treat early stages of PD, has been shown to mediate the 
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GAPDH-Siah-1 apoptotic pathway (Hara et al., 2006).  Deprenyl was shown to 
reduce the amount of GAPDH nitrosylation (Hara et al., 2006).  The reduction in 
GAPDH nitrosylation is associated with a reduction in nuclear GAPDH because 
there is less GAPDH that is capable of interacting with Siah-1 (Hara et al., 2006). 
Here we hypothesize that DNSP-11 is also able to reduce the amount of nuclear 
GAPDH by interacting with the GAPDH pathway.  Additionally, it is hypothesized 
that through mediating the GAPDH apoptotic pathway, DNSP-11 is able to 
reduce the observed amount of apoptosis.
VIII. Thesis outline
The data presented here involves the evaluation of the molecular and 
cellular mechanism of DNSP-5, DNSP-11, and DNSP-17, which are derived from 
prosequence of GDNF.  Initial studies were carried out to evaluate the physical 
characteristics of these three peptides.  Cell culture assays and proteomic 
profiling were utilized to determine binding partners and potential mechanisms 
through which DNSP-11 may be able to mediate apoptosis.  These studies will 
not only contribute to the understanding of neurotrophic factor prosequence 
function, but will also serve as a starting point for the development of novel 
trophic factors for PD treatment.  Finally, the interaction between DNSP-11 and 
GAPDH was evaluated as a potential anti-apoptotic mechanism.
38
A B 
Figure 1.1: The history of Parkinson’s disease.  (A) shows a statue of Wilhelm 
von Humboldt (1767-1835) by Friedrich Drake.  This statue shows the stooped 
posture of von Humboldt which is characteristic of PD.  von Humboldt also 
described his other neurological symptoms, including tremor and bradykinesia, in 
letters (Horowski et al.,  1995). (B) James Parkinson wrote “An Essay on the 
Shaking Palsy” in 1817 (Parkinson, 2002).  It was the first description of PD and 
described six cases that Parkinson observed as patients or on the streets. 
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Figure 1.2: Changes in signaling in the basal ganglia in Parkinson’s disease. (A) 
shows the signaling pathway between the neurons of the basal ganglia in normal 
brain. In Parkinson’s disease, the loss of neurons within the substantia nigra 
result in changes within the signaling pathway (shown in (B)) that result in the 
observed loss of motor control. Key: Red arrows indicate inhibitory input, blue 
arrows indicate excitatory input, purple indicates both inhibitory and excitatory 
input. The thickness of the arrow indicates the relative amount of input. Modified 
from Wichmann and Dostrovsky, 2011 (SNr - substantia nigra pars reticulata; 
SNc - substantia nigra pars compacta; GPi - globus pallidus: internal segment; 
GPe - globus pallidus: external segment; STN -subthalamic nucleus).
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Table 1.1: Genetics of Parkinson’s disease. The genes that have been linked to 
familial Parkinson’s disease are displayed here along with their position, 
inheritance pattern, and the type of Parkinsonism that results from each 
mutation. Modified from Bekris et al., 2010.
PARK Locus Gene Map Position Inheritance
Type of 
Parkinsonis
m
PARK1/
PARK4 SNCA 4q21 AD EOPD
PARK2 Parkin 6q25.2-q27 AR Juvenile and EOPD
PARK6 PINK1 1p35-p36 AR EOPD
PARK7 DJ-1 1p36 AR EOPD
PARK8 LRRK2 12q12 AD EOPD
PARK9 IATP13A2 1p36 AR Kufor-Rakeb syndrome
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Table 1.2: Current Parkinson’s disease treatments. The current therapeutics for 
PD are displayed here along with the mechanism of each of the treatments 
(Mayo Clinic, 2012).
Drug Name Drug Class
Selegiline MAO-B Inhibitor
Rasagiline MAO-B Inhibitor
Pramipexole Dopamine Receptor Agonist
Ropinirole Dopamine Receptor Agonist
Levodopa Dopamine Replacement
Entacapone COMT Inhibitor
Carbidopa Dopa-decarboxylase Inhibitor
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Levodopa 
Figure 1.3: Mechanisms of current Parkinson’s disease treatments. The current 
standard treatment for PD is levodopa. Levodopa can be delivered systemically 
and cross the blood brain barrier. Once it reaches the brain it can be converted to 
dopamine. In order to prevent levodopa from being converted to dopamine 
outside of the brain, it is often given in combination with carbidopa, a dopa-
decarboxylase inhibitor. Additionally, MAO-B inhibitors, which prevent dopamine 
from being broken down in the brain, can be used to treat PD. As a replacement 
for the lost dopamine, dopamine agonists can be used to activate dopamine 
receptors (Lopex et al., 2001; Factor, 1999).
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Table 1.3: Interaction of dopamine agonists with dopamine receptors. The 
interaction between common dopamine agonists and the dopamine receptors is 
summarized here. Most of the currently available dopamine agonists interact with 
the D2 receptor; however, there is cross talk with other dopamine receptors. 
Modified from Factor, 1999.
Dopamine Agonist D1 D2 D3 D4 D5
Dopamine + ++ +++ ++ +++
Bromocriptine - ++ + + +
Pergolide + +++ +++ +++ +
Pramipexole - +++ +++ ++ -
Ropinirole - +++ +++ - -
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Figure 1.4: GDNF family interactions with GFRα receptors. The GDNF family of 
proteins interact with the GFRα family of receptors, in addition to the RET 
receptor, to initiate a variety of intracellular pathways. The interaction of the 
GDNF proteins is shown here. GDNF has been shown to primarily interact with 
GFRα1, while interacting with GFRα2 to a lesser extent. NTN preferentially 
interacts with GFRα2 with some cross talk with GFRα1. ARTN may bind to 
GFRα1, but predominantly interacts with GFRα3. Finally, PSPN has been shown 
to only interact with GFRα4 (Saarma, 2000).
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Figure 1.5: NGF and proNGF’s roles in cell survival. Mature NGF has been 
shown to promote cell survival by interacting with the TrkA receptors. However, 
the proNGF interacts with the a heterodimer consisting of p75NTR and sortilin. 
When proNGF interacts with this receptor it initiates cell death instead of cell 
survival. Modified from Nykjaer et al., 2004.
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Figure 1.6: Processing of the DNSPs. GDNF is originally produced as a 
preproprotein. This protein is processed in the rough endoplasmic reticulum and 
golgi complex for secretion. It is hypothesized that during this processing three 
amidated peptides of 5, 11, and 17 amino acids in length are produced as a 
result of the presence of internal endopeptidase sites identified with in the 
proGDNF sequence (Bradley et al, 2010).
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Figure 1.7: Role of GAPDH in mediating apoptosis. It has been observed that 
GAPDH is involved in mediating an apoptotic pathway. As part of this pathway, 
GAPDH becomes nitrosylated after which the nitrosylated GAPDH is capable of 
binding to Siah1, an E3 ubiquitin ligase. The binding of GAPDH to Siah1 
stabilizes the normally unstable Siah1. The GAPDH-Siah1 complex then moves 
into the nucleus, where Siah1 degrades its nuclear targets and initiates 
apoptosis. Modified from Hara et al., 2005
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Chapter Two: Methods
I. Stability study
 Individual (0.3 and 1.0 mg/mL) and combination solutions of DNSP-5, 
DNSP-11, and DNSP-17 were made in sterile citrate buffer (10 mM Citrate + 150 
mM NaCl, pH 5.0).  Samples were then stored at -80°C and 37°C for 0, 3, 7, 10, 
14, 17, 21, 25, 28, or 31 days.  At these intervals, aliquots were analyzed for 
degradation using RP-HPLC (Waters Breeze System) with dH2O (HPLC grade) 
+ 0.1% trifluoroacetic acid (TFA) as the aqueous mobile phase.  Samples were 
loaded to a C4 column (4.6 mm 75 mm, 300 Å pore size, GRACE/Vydac 
214TP54, Deerfield, IL) at a flow rate of 1 mL/min and the column flow through 
was monitored at 214 nm with a Waters 2486 dual-wavelength UV/VIS detector.  
Samples were eluted with a linear gradient of the organic mobile phase 
(acetonitrile + 0.1% TFA), to a final aqueous:organic phase ratio of 75:25 after 30 
min.  All solvents were HPLC grade, degassed and filtered prior to use. At 31 
days, aliquots were subjected to LC-MS analysis.
II. Far-UV circular dichroism spectroscopy
 Circular dichroism (CD) measurements were performed for each purified 
peptide sample (DNSP-5, 130 μM; DNSP-11, 21 μM; DNSP-17, 13 μM) in 50 mM 
sodium phosphate buffer, pH 7.0.  Measurements were made in a 1 mm quartz 
cuvette using a Jasco J-810 spectrophotometer.  Spectra were recorded as the 
49
average of four far-UV wavelength scans from 250 to 190 nm with 0.5 nm steps 
and 8 s averaging time.
III. Heparin affinity chromatography
Peptide and GDNF samples (10 μM) in 10 mM sodium citrate, pH 5.6 were 
loaded to a 1 mL HiTrapTM Heparin HP Column (GE Healthcare) at 1mL/min.  
Column elutant was simultaneously monitored for peptide/protein (k = 215 nm) 
and salt concentration using an AKTA Explorer 100 equipped with UV/Vis 
detector and conductivity monitor.  Following column loading and washing, 
heparin-binding samples were eluted with a high-salt linear gradient (10 mM 
sodium citrate + 2 M NaCl, pH 5.6).  All buffers were freshly prepared, filtered 
and degassed prior to use.
IV. Caspase-3 activity assay
HEK-293 cells were plated to 100,000 cells/well.  Cell cultures were 
exposed to defined dosages of DNSP-5, DNSP-11, or DNSP- 17 and either 1 μM 
staurosporine or 8 mM 3-nitropropionate exposure.  The Enz Chek (Invitrogen) 
caspase-3 kit was used to monitor caspase-3 activity.  Fluorescence 
measurements were made after 12 h of treatment (excitation/emission 496/520 
nm) using a Molecular Devices Spectramax M5 plate reader.  Protein levels of 
lysed cells were measured by BCA assay (BioRad) and normalized for every 
experiment.  Data are expressed as percent of control and were repeated a 
minimum of 3 times.
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V. Terminal dUTP nick-end labeling (TUNEL)
 After treatment with DNSP-11, cells are fixed and labeled to assess 
degenerative nuclear changes as indicated by the extent of high-molecular 
weight DNA strand breaks. This was performed by the Apo-BrdU TUNEL Assay 
(Invitrogen).
VI. Pull down analysis with isolated substantia nigra from young Fischer 344 rats
Young F344 substantia nigra tissue samples are homogenized in Buffer A 
(20 mM HEPES, pH 7.5, 10% Glycerol, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, 
CompleteTM Mini EDTA Free tablet (for 10 mL; Roche)). Samples are then 
centrifuged for 30 minutes at 100,000 x g at 4°C, and the supernatant (cytosolic 
fraction) is collected. Buffer B (Buffer A plus 0.5% Brig 58) is then added to the 
pellet, mixed thoroughly, and incubated on ice for 15 minutes. The samples are 
then centrifuged for 30 minutes at 100,000 x g at 4°C. The supernatant 
(membrane bound fraction) is then collected (pellet discarded). 50 μg of the 
bDNSP-11 is added to both the cytosolic and membrane bound fractions and 
incubated for 15 minutes on ice. The samples are then added to 125 μL aliquot of 
streptavidin magnetic beads (New England Biolabs, Beverly MA) to isolate bound 
proteins. The beads are extensively washed (three times) in 100 μL Buffer A 
(cytosolic) or 100 μL Buffer B (membrane bound). Bound proteins will be eluted 
from the beads with 2x50 μL of Solubilization/Rehydration Solution (7 M Urea, 2 
M Thiourea, 50 mM DTT, 4% CHAPS, 1% NP-40, 0.2% Carrier ampholytes, 
0.0002% Bromophenol blue) and then once with 100 μL of Solubilzation/
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Rehydration Solution.  Aliquots were pooled and the proteins are analyzed by 
2D-PAGE and identified by matrix-assisted laser desorption/ionization-time of 
flight (MALDI-TOF) mass spectrometry.
VII. In vitro pull down of GAPDH
Binding studies were performed using purified samples of GAPDH 
(Sigma) and bDNSP-11.  The two were incubated together in binding buffer (50 
mM Tris, pH 7.4, 150 mM NaCl, 0.1 mg/ml BSA, 50 μM NAD+, 10 mM sodium 
phosphate, 50 μM Glyceraldehyde-3-phosphate) at 4°C for 1 hour. The sample 
were then mixed with streptavidin magnetic beads and incubated at 4°C for 1 
hour and washed three times with binding buffer.  The protein was then removed 
from the beads with SDS sample running buffer.  The samples were separated by 
SDS-PAGE.
VIII. In vitro S-nitrosylation of GAPDH
Based on the procedure described by Jaffrey et al., 2001. Pure GAPDH 
(Sigma) is pretreated with either S-nitrosoglutathione (GSNO, active NO donor) 
or glutathione (inactive control). Following incubation at RT in the dark, unreacted 
GSNO/glutathione is removed by four buffer exchanges into binding buffer (50 
mM Tris pH 7.4, 150 mM NaCl, 0.1 mg/ml BSA, 50 µM NAD+, 10 mM sodium 
phosphate, and 50 µM glyceraldehyde-3-phosphate) using a Amicon Ultra 5,000 
MWCO spin column.
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IX. In vitro pull down assay
A solution of 25 µL GFRα1 (1 mg/mL) was incubated with 50 µL of 
Dynabeads® (Invitrogen) in wash and bind buffer (0.1 M sodium phosphate, pH 
8.2, 0.01% Tween® 20) for 10 minutes at room temperature.  The beads were 
then washed three times in 100 µL of wash and bind buffer.  2 µg of GDNF was 
added and incubated for 1 hour at 4°C. 25 µL GFRα1 (1 mg/mL) was incubated 
with 40 µg of biotinylated DNSP-11 (bDNSP-11) for 1 hour at 4°C. They were 
then added to 50 µL of hydrophilic streptavidin magnetic beads (New England 
Biolabs) and incubated for an hour at 4°C.
X. Western blots
Protein concentrations were determined by performing a Bradford.  
Samples were then normalized to 30 μg of total protein.  The samples were run 
on a 10% acrylamide gel for 1.5 hours at 200 volts.  The gels were then 
transferred onto PVDF membrane at 200 mA for 45 minutes.  Membranes were 
then blocked with 5% milk for 2 hours at room temperature.  After being washed 
three times for five minutes each with 1X Tris buffered saline with Tween (TSB-
T), the membranes were incubated overnight at 4°C with primary antibody.  The 
membranes were then washed three times for five minutes each with 1X TBS-T 
and incubated with the corresponding secondary antibody for 2 hours at room 
temperature.  Staining was imaged on the Odyssey and the Odyssey software 
package (LI-COR) was used to calculate the amount of protein present for 
analysis.
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Chapter 3: Evaluation of the physical and in vitro protective activity of three 
synthetic peptides derived from the pro- and mature GDNF sequence
I. Introduction
Glial cell line-derived neurotrophic factor (GDNF), due to its potent and 
specific neurotrophic effects on dopaminergic neurons (Lin et al., 1993), has 
been extensively examined as a therapeutic agent for the treatment of age-
related neurodegenerative diseases, such as Parkinson’s disease (PD) (Gash et 
al., 1996; Gill et al., 2003; Lang et al., 2006; Slevin et al., 2005).  However, 
GDNF has not advanced beyond phase II clinical trials, primarily due to 
challenges attributed to the direct intracranial delivery of large proteins (Gash et 
al., 2005; Lang et al., 2006; Patel and Gill, 2007; Salvatore et al., 2006).  
Furthermore, GDNF binds heparin with high affinity (Lin et al., 1993, 1994), and 
likely other heparin-related molecules abundant in the brain matrix (Rickard et al., 
2003; Sariola and Saarma, 2003), which hinders its predictable biodistribution 
following a direct injection (Gash et al., 2005; Lapchak et al., 1998; Patel and Gill, 
2007; Piltonen et al., 2009; Salvatore et al., 2006).
 While additional delivery strategies have been examined to improve GDNF 
delivery and distribution in vivo, including convection enhanced delivery (CED) 
(Fiandaca et al., 2008; Hamilton et al., 2001; Morrison et al., 2007), co-infusion 
with heparin during CED (Hamilton et al., 2001), removal of the GDNF N-terminal 
heparin binding domain (Piltonen et al., 2009), viral vector delivery (Kordower et 
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al., 2000; Ramaswamy et al., 2009; Wang et al., 2002) and encapsulated GDNF-
producing cells (Lindner et al., 1995; Lindvall and Wahlberg, 2008), they have not 
advanced to clinical applications.  The challenges associated with the delivery 
and distribution of large molecules to the central nervous system (CNS) have led 
to exploration of alternative approaches.  One such approach to circumvent 
these delivery and distribution challenges would be to utilize small, neurotrophic-
like functional molecules.
 Recently, it has been hypothesized that functional, carboxy-terminally 
amidated peptides of 5, 11, and 17 amino acids are processed from the rodent 
and human GDNF precursor and mature sequences upon proteolytic cleavage 
by furin-like endopeptidases (Bradley et al., 2010; Immonen et al., 2008).  Based 
on initial studies showing all three peptides possessed some dopaminergic 
activities, they were named dopamine neuron stimulating peptides (Bradley et al., 
2009).  While these peptides have not been isolated endogenously to date, initial 
studies in rat hippocampal CA1 pyramidal neurons showed that the rat 11-mer 
sequence (named brain excitatory peptide, BEP) significantly induced synaptic 
excitability, while the 5- and 17-mer sequences failed to show statistical 
significance (Immonen et al., 2008).  Furthermore, we have shown the human 11-
mer sequence (named dopamine neuron stimulating peptide-11, DNSP-11) 
exhibits neurotrophic-like properties including (i) promotion of the survival of 
primary fetal mesencephalic neurons; (ii) in vitro protection from 6-
hydroxydopamine (6-OHDA) in primary mesencephalic and MN9D dopaminergic 
cell culture; (iii) improving the neurochemical resting levels of dopamine and its 
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metabolites for up to 28 days following a single injection into the rat substantia 
nigra; and (iv) significantly improving apomorphine-induced rotational behavior in 
a severe, PD rat model (Bradley et al., 2010).  Collectively, these data support 
the further characterization and translational evaluation of these peptides as lead 
therapeutic candidates.
Here data is presented to show the initial in vitro physical characterization of 
DNSP-5, DNSP-11, and DNSP-17.  We show that all three peptides are soluble 
and stable under a variety of conditions in vitro.  In addition, DNSP-5 and 
DNSP-11 are shown to not interact with heparin, which would enhance their in 
vivo biodistribution following delivery to the brain.  Finally, it is shown that 
DNSP-11 offers significant protection, from both staurosporine- and 3-
nitropropionate (3-NP)-induced cytotoxicity in HEK-293 cells, supporting the 
potential for broad beneficial effects on other, non-neuronal cell types.  These 
data provide the basis for future evaluation and development of the dopamine 
neuron stimulating peptides as a disease modifying therapeutic.
II. Methods
a. Stability study
Individual (0.3 and 1.0 mg/mL) and combination solutions of DNSP-5, 
DNSP-11, and DNSP-17 were made in sterile citrate buffer (10 mM Citrate + 150 
mM NaCl, pH 5.0).  Samples were then stored at -80°C to 37°C for 0, 3, 7, 10, 
14, 17, 21, 25, 28, or 31 days.  At these intervals, aliquots were analyzed for 
degradation using RP-HPLC (Waters Breeze System) with dH2O (HPLC grade) 
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+ 0.1% trifluoroacetic acid (TFA) as the aqueous mobile phase.  Samples were 
loaded to a C4 column (4.6 mm 75 mm, 300 Å pore size, GRACE/Vydac 
214TP54, Deerfield, IL) at a flow rate of 1 mL/min and the column flow through 
was monitored at 214 nm with a Waters 2486 dual-wavelength UV/VIS detector.  
Samples were eluted with a linear gradient of the organic mobile phase 
(acetonitrile + 0.1% TFA), to a final aqueous:organic phase ratio of 75:25 after 30 
min.  All solvents were HPLC grade, degassed and filtered prior to use. At 31 
days, aliquots were subjected to LC-MS analysis.
b. Far-UV circular dichroism spectroscopy
 Circular dichroism (CD) measurements were performed for each purified 
peptide sample (DNSP-5, 130 μM; DNSP-11, 21 μM; DNSP-17, 13 μM) in 50 mM 
sodium phosphate buffer, pH 7.0.  Measurements were made in a 1 mm quartz 
cuvette using a Jasco J-810 spectrophotometer.  Spectra were recorded as the 
average of four far-UV wavelength scans from 250 to 190 nm with 0.5 nm steps 
and 8 s averaging time.
c. Heparin affinity chromatography
 Peptide and GDNF samples (10 μM) in 10 mM sodium citrate, pH 5.6 were 
loaded to a 1 mL HiTrapTM Heparin HP Column (GE Healthcare) at 1mL/min.  
Column elutant was simultaneously monitored for peptide/protein (λ = 215 nm) 
and salt concentration using an AKTA Explorer 100 equipped with UV/Vis 
detector and conductivity monitor.  Following column loading and washing, 
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heparin-binding samples were eluted with a high-salt linear gradient (10 mM 
sodium citrate + 2 M NaCl, pH 5.6).  All buffers were freshly prepared, filtered 
and degassed prior to use.
d. Caspase-3 activity assay
HEK-293 cells were plated to 100,000 cells/well.  Cell cultures were 
exposed to defined dosages of DNSP-5, DNSP-11, or DNSP- 17 and either 1 μM 
staurosporine or 8 mM 3-nitropropionate exposure.  The Enz Chek (Invitrogen) 
caspase-3 kit was used to monitor caspase-3 activity.  Fluorescence 
measurements were made after 12 h of treatment (λ excitation/λ emission 
496/520 nm) using a Molecular Devices Spectramax M5 plate reader.  Protein 
levels of lysed cells were measured by BCA assay (BioRad) and normalized for 
every experiment.  Data expressed as percent of control and were repeated a 
minimum of 3 times.
III. Results
a. RP-HPLC analysis and long-term stability of the DNSPs
 Reverse phase HPLC (RP-HPLC) was used to isolate and purify DNSP-5, 
DNSP-11, and DNSP-17 from an aqueous tripeptide mixture solution (Figure 
3.1A).  The individual DNSPs were separated from an aqueous tripeptide mixture 
solution on a C4 reverse phase column with increasing concentrations of 
acetonitrile, in an inverse relationship to their size (Table 3.1).  The identification 
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of each well-resolved peak was confirmed by liquid chromatography mass 
spectrometry (LC-MS) (Table 3.1).
 RP-HPLC and LC-MS were used to monitor the stability of DNSP- 5, 
DNSP-11, and DNSP-17.  The peptides were stored in citrate buffer (10 mM 
Citrate + 150 mM NaCl, pH 5.0) at -80°C and 37°C for 31 days and 4°C for one 
week.  These conditions were chosen based on their relevance to long-term 
storage and use in future in vivo translational studies.  The peptides were stable 
at all temperatures tested, thus allowing for the confident use of the individual 
peptides for further investigation when stored in vitro at these temperatures 
(Table 3.1, Figure 3.2).  Furthermore, LC-MS and amino acid sequencing data 
confirmed there was no intrinsic degradation within these sequences (i.e. 
deamidation) upon storage; each peptide sequence was as originally synthesized 
(Figure 3.2).  Additional studies performed at 4°C found no degradation at one 
week as determined by RP-HPLC.
b. Far-UV circular dichroism structural analysis
 The peptide backbone structure of DNSP-5, DNSP-11, and DNSP-17 were 
examined using circular dichroism (CD) spectroscopy in the far-UV region.  All 
three peptides exhibited a minimum ellipticity value between 196–200 nm, with 
small spectral signatures observed (shoulders between 208–230 nm), typical of 
small, soluble peptides of similar length sampling multiple backbone 
conformations including random coil, turn, polyproline II and α- helix (Figure 
3.1B).  Additionally, CD was utilized to determine if there are intermolecular 
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interactions between DNSP-5, DNSP-11, and DNSP-17 in vitro.  The tripeptide 
mixture has similar far-UV CD spectra as the additive spectra of the individual 
peptides, with minor differences at 200 nm that are within experimental error 
(Figure 3.1B), thus demonstrating that the three peptides do not interact in vitro.
c. Heparin binding analysis
 We investigated the heparin-binding properties of the DNSPs using heparin 
affinity chromatography.  Human GDNF binds tightly to the heparin Sepharose 
column, eluting at high salt concentrations [0.8 M NaCl] in 10 mM sodium citrate 
buffer (pH 5.6), consistent with earlier data (Lin et al., 1994).  DNSP-17, the 
sequence of which is present within the heparin binding N-terminus of mature 
GDNF, binds strongly to the heparin column with an identical elution profile to 
mature GDNF (Figure 3.3).  However, the peptides derived from the GDNF 
prosequence, DNSP-5 and DNSP-11, have no affinity for the heparin column, 
eluting in the column flow through (Figure 3.3).
d. Protection from staurosporine and 3-nitropropionate in HEK-293 cells
 While DNSP-11 has analogous in vivo neurotrophic-like properties, it likely 
functions differently than GDNF.  We showed that DNSP-11 does not directly 
interact with the physiological receptor of mature GDNF, GFRa1 (Bradley et al., 
2010).  Furthermore, treatment with 10 ng/mL (10 nM) DNSP-11 was shown to 
block 1 μM staurosporine-induced cytotoxicity in nutrient-deprived dopaminergic 
B65 cells, and its neuroprotective effects included preventing the release of 
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cytochrome c from mitochondria (Bradley et al., 2010).  DNSP-11 proteomic pull 
down studies identified 16 proteins by MALDI-TOF mass spectrometry, 11 of 
which possess metabolic functions (Bradley et al., 2010).  Collectively, these data 
support our hypothesis that DNSP-11’s neurotrophic effects are mediated 
through the mitochondria.
 To extend this line of investigation, we examined the protective roles of the 
DNSPs from the activation of caspase-3, a pro-apoptotic protein, in cultured non-
neuronal HEK-293 cells.  Following 12 h of staurosporine (1 μM) exposure, 
caspase-3 activity was significantly increased by approximately 80%, consistent 
with initiation of apoptosis (Figure 3.4A).  Between 10 to 100 nM, DNSP-11 
provided significant protection (return to control values) from staurosporine-
induced activation of caspase-3 (Figure 3.4A).  At dosages lower than 10 nM, the 
protective effects of DNSP-11 were not significant. Both DNSP-5 and DNSP-17 
did not provide any significant protection from staurosporine-induced activation of 
caspase-3 at the tested dosages in the non-neuronal cell line, with the exception 
of the lowest (1 nM) DNSP-17 dosage (Figure 3.4A).
 To determine if the protective effects were specific for mitochondria, we 
examined the protection afforded by the DNSPs against 3-nitropropionic acid (3-
NP) activation of caspase-3 activity in HEK-293 cells.  3-NP is an apoptosis-
inducing, mitochondrial specific toxin that irreversibly inhibits succinate 
dehydrogenase of the Kreb’s cycle and complex II of respiration, resulting in 
mitochondria membrane permeabilization and caspase-3 activation (Beal, 1994; 
Ludolph et al., 1991; Nasr et al., 2009; Palfi et al., 1996).  Exposure of 8 mM 3-
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NP to HEK-293 cells for 12 h significantly increased caspase-3 activity 
approximately 100% over control (Figure 3.4B).  At a same concentration (10 nM) 
that provided staurosporine protection, DNSP-11 provided significant protection 
from 3-NP induced activation of caspase-3 activity in HEK-293 cells, whereas 
equimolar concentrations of DNSP-5 and DNSP-17 provided no significant 
protection (Figure 3.4B).
IV. Discussion
 Neurotrophic factors have received considerable attention as potential 
therapeutic agents for neurodegenerative disorders, including PD.  However, 
because of unsuccessful clinical trials as well as prolonged patent protection/
litigation, the clinical applications of these native molecules have yet to be 
realized.  Large trophic factors, such as GDNF, have inherent pharmacological 
disadvantages and challenges: they must be delivered to the CNS by invasive 
procedures.  Thus, smaller molecules like the DNSPs, which are relatively easy 
to synthesize and modify to improve bioavailability, have the potential for more 
widespread use in the clinic (Thorne and Frey, 2001).
 Because of the stringent requirements of biotherapeutics for in vitro stability 
and solubility, the DNSPs were evaluated for these properties (Bell, 1997; 
Powell, 1994).  RP-HPLC and LC-MS data showed that each of the DNSPs were 
stable at -80°C and 37°C for one month without any appreciable loss or intrinsic 
modification of the peptides.  Other common storage and experimental 
temperatures tested had similar results, supporting that the DNSPs remain stable 
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for long-term storage and delivery, such as an internal implanted pump stored in 
the abdominal cavity holding one month’s supply of peptide.  Additional evidence 
supports long term storage of the peptide at -80°C and shows that peptides still 
retain their potency and protection after storage for up to 2 years (Bradley et al., 
unpublished data).  Thus, the DNSPs are stable in vitro, which is essential if they 
are to be used in clinical applications.
 It was hypothesized that the processed DNSPs might have endogenous/
physiological function.  It is possible that the DNSPs form an intermolecular 
complex for bioactivity.  We show that the far-UV CD spectra of the individual 
DNSPs are an additive for the tripeptide mixture, thereby suggesting that these 
peptides do not interact in vitro.  These spectra show dynamic structural 
characteristics that would be expected of small, soluble peptides of 5, 11, and 17 
amino acids.  Furthermore, this data shows no signs of aggregation of the 
peptides, which could lead to complications with delivery and potentially activate 
an immune response.
 To gain insight into the biodistribution properties of the DNSPs, we examined 
their heparin binding properties by affinity chromatography. Heparin binding has 
been shown to limit the biodistribution of GDNF, thereby affecting its therapeutic 
targeting following an intracranial injection (Gash et al., 2005; Lapchak et al., 
1998).  Unlike mature GDNF, both DNSP-5 and DNSP-11 do not bind heparin 
(Figure 3.3), thus suggesting that the GDNF prosequence-derived peptides 
would have enhanced volume of distribution properties when delivered 
intracranially.  Although the apparent lack of heparin binding might make it 
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difficult to control the diffusion of these peptides into non-targeted/undesired 
regions of the brain, our previous immunohistochemical staining data with 
DNSP-11 showed rapid uptake into neurons found both in the substantia nigra, 
pars reticulata and substantia nigra, pars compacta within 30 min following a 
direct injection (Bradley et al., 2010).  Furthermore, increased resting levels of 
dopamine and its metabolites were observed for up to 28 days in normal and 6-
OHDA-lesioned Fischer 344 rats following a single injection of DNSP-11 into the 
substantia nigra, with no adverse effects observed under these conditions 
(Bradley et al., 2010).  In vivo studies with DNSP-5 are currently ongoing.
 Heparin affinity chromatography of DNSP-17, an amidated 17 amino acid 
sequence putatively derived from amino acids 13–29 within the N-terminal region 
of mature GDNF, exhibited an equal binding profile as GDNF (Figure 3.3).  These 
data are consistent with earlier studies, which have demonstrated that heparin 
binding activity is located within the GDNF N-terminal domain, however, the 
residues primarily responsible for heparin binding are unresolved (Alfano et al., 
2007; Parkash et al., 2008; Piltonen et al., 2009).  Complete removal of the 
highly-basic, 38 amino acid residue N- terminal domain resulted in an elimination 
of heparin binding and increased GDNF biodistribution in vivo (Piltonen et al., 
2009).  Recent data from the crystal structure of the GDNF-GFRa1 complex, 
show basic GDNF residues Arg35, Lys37, and Arg39 to be interacting with 
sucrose octasulfate, a heparin mimic (Parkash et al., 2008).  However, GDNF 
residues 1–34 were unresolved in the receptor-complex crystal structure 
(Parkash et al., 2008) to rule out additional binding sites. In an earlier study, 
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ELISA and affinity chromatography data showed that removal of the N-terminal 
domain residues 24–39 (ND2) resulted in a weakening of heparin binding, 
whereas deletion of residues 4–23 (ND1) had little change relative to full-length 
GDNF (Alfano et al., 2007).  Given DNSP-17’s strong heparin-binding properties, 
this suggests that a significant portion of the N-terminal GDNF heparin binding 
domain is provided by this sequence, likely the two dibasic BXB clusters at the N- 
and C-terminal ends of the peptide sequence (corresponding to mature GDNF 
residues Arg14, Arg16, Arg27, and Lys29).  Thus, DNSP-17 could provide a 
further tool towards understanding of the unresolved role of heparin binding and 
GDNF signaling (Alfano et al., 2007; Piltonen et al., 2009).  Additionally, 
DNSP-17 may serve as a co-infusate with GDNF to improve its distribution 
following a direct injection or CED.
 DNSP-11 appears to be a functional proGDNF-derived peptide. Initial studies 
of the rat homolog of DNSP-11, BEP, showed a significant increase in synaptic 
excitability of rat CA1 pyramidal neurons, as well as broad-binding within the 
adult rat brain (Immonen et al., 2008).  Additional studies demonstrated that 
DNSP-11 exhibits neurotrophic-like effects in vivo, including long-lived increases 
in rat resting dopamine levels following a single nigral injection (Bradley et al., 
2010).  Furthermore, DNSP-11 was shown to be protective at a single dose from 
6-OHDA, staurosporine and gramicidin cytotoxins in dopaminergic cell lines 
(Bradley et al., 2010).  Consistent with these prior observations, DNSP-11 
provides significant dose-dependent protection from staurosporine and 3-NP in 
the non-neuronal, HEK-293 cell line (Figure 3.4A, B).  While staurosporine is a 
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broad-based cytotoxin, 3-NP targets succinate dehydrogenase of the respiratory 
complex II of the mitochondrial electron transport chain, supporting that 
DNSP-11’s protective mechanism of action involves mitochondria.  These data 
are further supported by recent findings showing protection from specific 
mitochondrial toxins (Turchan-Cholewo et al., submitted).
 Unlike DNSP-11, DNSP-5 did not provide significant protection from 
staurosporine and 3-NP in HEK-293 cells.  In addition, DNSP-17 showed limited 
protection from staurosporine (only at 1 nM) and failed to produce 3-NP 
protection.  Previous work further demonstrated that the DNSP-5 and the 
DNSP-17 peptide sequences failed to produce significant neuronal excitability 
(Immonen et al., 2008).  Collectively, these early findings support a limited 
mitochondrial protective role for DNSP-5 and DNSP-17.  However, given the 
findings with DNSP-11, further studies are warranted to establish the possible 
functional roles of these relatively unexplored sequences.
V. Conclusion
The emergence of naturally occurring, physiologically functional propeptides  
from the neurotrophic factor family provides a wealth of untapped sequences for 
exploration and evaluation.  As these newly characterized peptides undergo 
further therapeutic evaluation, it is necessary to conduct studies with molecules 
characterized under a variety of experimental and storage conditions for 
reproducibility and translation.  Here we show that the DNSPs are inherently 
stable and soluble under these conditions.  Of the three peptides, DNSP-5 and 
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DNSP-11 do not bind heparin, which would facilitate their biodistribution 
properties when delivered in the brain.  Finally, we show that DNSP-11 exhibits 
protection from the cytotoxins staurosporine and 3-NP, in HEK-293 cells, 
supporting a potentially broad role as a disease altering therapeutic.
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Figure 3.1: Physical characterization of the DNSPs. (A) A tripeptide mixture of 
DNSP-5, DNSP-11, and DNSP-17 was loaded to a C4 column in dH2O and 0.1% 
TFA. After ten minutes of wash (1 mL/min), samples were eluted with a linear 
gradient (red) of the organic mobile phase (acetonitrile + 0.1% TFA), to a final 
aqueous:organic phase ratio of 75:25 after 30 minutes. Elution of the peptides 
was monitored at 214 nm. (B) Far-UV CD analysis of DNSP-5 (open circles), 
DNSP-11 (gray squares), and DNSP-17 (back triangles) shows that the peptides 
have backbone characteristics of small, soluble peptides (Kelps et al., 2011).
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Table 3.1: Characterization of the DNSPs in vitro stability after incubation at 37°C 
for 31 days. Integration of the RP-HPLC elution peaks for each of the DNSPs 
were used to calculate the percent of peptide remaining after incubation at 37 °C 
for 31 days. These samples were then submitted to mass spectrometry, in which 
the determined molecular weight following extended incubation was in 
agreement with the calculated sequence molecular weight (Modified from Kelps 
et al., 2011).
Propeptid
e
Retention 
Time
% 
Acetonitril
e
Calculated 
Molecular 
Weight
Molecular 
Weight 
After 30 
Days 
(37°C)
% 
Remainin
g After 30 
Days 
(37°C)
DNSP-5 24.4 19.4% 542 542.1 93.6%
DNSP-11 20.2 15.2% 1180 1180.3 97.6%
DNSP-17 15.5 10.5% 1868 1868.1 94.6%
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Figure 3.2:The CD analysis of the stability of the DNSPs in vitro. (A) shows the 
locations of the sequences of the proposed DNSPs.  (B) shows an HPLC 
purification of DNSP-5, 11, and 17.  The DNSP-5 was shown to be stable (C) for 
up to one month at 37°C by HPLC analysis. The DNSP-11 was shown to be 
stable (D) for up to one month at 37°C by HPLC analysis. The DNSP-17 was 
shown to be stable (E) for up to one month at 37°C by HPLC analysis (Modified 
from Kelps et al., 2011).
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Figure 3.3: Heparin affinity chromatography of the DNSPs and GDNF. 10 μM 
samples of the synthetic DNSPs and GDNF (in 10 mM sodium citrate, pH 5.6) 
were applied to a HiTrap™ Heparin HP affinity column and elutant was monitored 
at 215 nm. After sample loading and wash, a high salt (10 mM sodium citrate + 2 
M NaCl) linear gradient was applied (dashed line) to elute heparin-binding 
samples (Modified from Kelps et al., 2011).
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Figure 3.4: Protective effects of the DNSPs. (A) Dose responses (1 nM – 100 
nM) for DNSP-5 (blue bars), DNSP-11 (black bars), and DNSP-17 (gray bars) 
protection from 1 μM staurosporine-induced cytotoxicity (red bar), were 
measured by caspase-3 activity 12 hours after treatment in HEK-293 cells. 
Stauro-staurosporine. (B) Protection from 8 mM 3-nitropropionate (3-NP) was 
measured by caspase-3 activity assay 12 hours after treatment with 10 nM 
treatment with the DNSPs. For both experiments, the control (open bar) was 
citrate buffer alone. One-way ANOVA was used to test for significance amongst 
groups, followed by Tukey’s post-hoc analysis (*p<0.05, **p<0.01 vs control; 
#p<0.05, ##<0.0172 vs toxin) (Modified from Kelps et al., 2011).
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Chapter 4: Role of GAPDH in DNSP-11 protection
I. Introduction
Mature glial cell line-derived neurotrophic factor (GDNF) has been shown 
to provide neuroprotective and neurorestorative effects in cellular and animal 
models of Parkinson’s disease (PD).  Based on the observed protective effects of 
GDNF, it advanced to clinical trials, but was not able to advance beyond that 
point, partially because of problems associated with using large molecule 
biotherapeutics, including production and delivery of these molecules to the 
brain.  
GDNF, which was originally identified in 1993 (Lin et al., 1993), is a 
member of the transforming growth factor-β (TGF-β) superfamily.  Mature GDNF 
has been shown to exhibit trophic effects on embryonic dopaminergic neurons 
(Tomac et al., 1995), spinal motor neurons (Henderson et al., 1994), and central 
noradrenergic neurons (Arenas et al., 1995).  GDNF has been shown to provide 
its observed protective effects primarily through its interaction with the receptor 
GDNF family receptor α1 (GFRα1) (Jing et al., 1996; Treanor et al., 1996).  After 
GDNF binds to GFRα1, it activates the receptor tyrosine kinase (RTK), Ret (Jing 
et al., 1996; Treanor et al., 1996; Trupp et al., 1996).  Through the interactions of 
GDNF with GFRα1 and Ret, GDNF is able to support cell survival by reducing 
the observed pro-apoptotic activity of Ret when it is not in the presence of GDNF 
(Bordeaux et al., 2000).  
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While GDNF has been shown to provide neuroprotective and 
neurorestorative effects in some models of PD, these protective effects have not 
been universally observed in all models of the disease.  Studies have shown that 
preadministering GDNF is not able to reduce α–synuclein-induced death of 
dopaminergic neurons (Decressac et al., 2011).  Treatment with GDNF was also 
unable to improve behavior in this PD model (Decressac et al., 2011).
Thus, alternative therapies that provide neuroprotection, while working via 
a nonGFRα1/RET pathway might be needed to treat certain forms of PD.  Small 
molecules with similar proposed therapeutic potential have been evaluated as 
possible alternatives to GDNF.  Three peptides of 5, 11, and 17 amino acids in 
length were identified as potential endogenous processing products (Bradley et 
al., 2010).  Preliminary evaluations of these three peptides show similar 
functional effects as mature GDNF, thus making them viable candidates for 
further development as a potential PD therapeutic.  The peptides have been 
shown to increase neurite outgrowth in primary mesocephalic cell culture models, 
as well as positively affect the behavior in a young Fisher 344 rat model of 
dopaminergic dysfunction (Bradley et al., 2010).  Treatment with DNSP-11 has 
been shown to increase basal dopamine (DA), dihydroxyphenylacetic acid 
(DOPAC), and homovanillic acid (HVA) in Fisher 344 rats (Fuqua, 2010).  While 
the cellular mechanism of these peptide sequences is unknown, these results 
coupled with the functional data from other neurotrophic factor prosequences, 
strongly suggest that the GDNF family of prosequences exhibit in vivo functions.  
Based on the observed anti-apoptotic effects in cellular models of DNSP-11, it 
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was hypothesized that DNSP-11 functioned through a similar mechanism to 
mature GDNF (Bradley et al., 2010).
The mechanism by which DNSP-11 is able to provide its observed 
protective effects and antiparkinsonian properties is not known.  Here, that 
mechanism is investigated.  Since DNSP-11 was derived from the sequence of 
GDNF and had been observed to support cell survival similar to mature GDNF 
(Bradley et al., 2010), initial studies looking at DNSP-11’s potential interactions 
with GFRα1 were conducted.  These initial binding studies did not indicate an 
interaction between DNSP-11 and GFRα1 (Bradley et al., 2010).  Based on the 
lack of evidence to support DNSP-11 functioning through the same mechanism 
as mature GDNF, proteomic studies were carried out in order to identify other 
potential binding partners.  In so doing, several potential binding partners were 
identified.  One of these binding partners was glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH).  
GAPDH is an enzyme that catalyzes the phosphorylation of 
glyceraldehyde-3-phosphate – a process requiring inorganic phosphate and 
nicotinamide adenine dinucleotide (NAD) - during carbohydrate metabolism.  
Because of GAPDH’s role in carbohydrate metabolism, it is abundant in the 
cytoplasm of all cells.  The abundance of GAPDH makes it suitable for many 
cellular assays as a control for protein levels within the cell.
GAPDH has previously been shown to be involved in mediating an 
apoptotic pathway (Hara, M.R. et al., 2005).  Under conditions of cellular stress, 
GAPDH has been shown to become nitrosylated.  This observed nitrosylation 
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occurs on cysteine 150 (Padgett, C.M. and Whorton A.R., 1995).  Once this 
nitrosylation occurs, GAPDH is no longer metabolically active, leaving two 
distinct pools of GAPDH in stressed cells.  The nitrosylated GAPDH can then 
interact with and bind to Siah-1, an E3 ubiqutin ligase.  When Siah-1 is not bound 
to GAPDH, Siah-1 is normally unstable and so it is quickly degraded within the 
cell (Hara, M.R. et al., 2005).  However, binding to nitrosylated GAPDH stabilizes 
Siah-1 and prevents it from being quickly degraded, allowing it to have prolonged 
effects.  GAPDH lacks a nuclear localization signal, so it normally is not found 
within the nucleus.  Conversely, Siah-1 possesses a nuclear localization signal 
and can therefore move into the nucleus.  Therefore, when nitrosylated GAPDH 
binds to Siah-1, it is able to move into the nucleus.  Since the binding of 
nitrosylated GAPDH helps to stabilize Siah-1, it is able to degrade its nuclear 
targets for an extended period of time (Hara, M.R. et al., 2005).  This leads to 
activation of an apoptotic pathway.
Based on the observed interaction between DNSP-11 and GAPDH and 
GAPDH’s role in apoptosis, it was hypothesized that DNSP-11’s protective 
mechanism are through a non-GFRα1 mediated mechanism and further 
hypothesized that GAPDH plays a role in this protection.  The effect of DNSP-11 
on GAPDH nitrosylation was determined by looking at levels of nuclear GAPDH, 
which is elevated after nitrosylation has occurred.  In addition to looking at 
nuclear GAPDH levels, GAPDH activity assays were used to determine if 
changes in nitrosylation levels occurred after treatment of GAPDH with DNSP-11.
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Presented here is the initial investigation regarding the cellular mechanism 
of DNSP-11’s anti-apoptotic effects.  Also, data evaluating the possible 
interactions between DNSP-11 and GFRα1 as a potential pathway through which 
DNSP-11 offers anti-apoptotic activity is presented.  DNSP-11’s role in a 
feedback mechanism resulting in an upregulation of GDNF mRNA and protein is 
also investigated.  Finally, a proteomic screen of potential binding partners in 
which GAPDH, a protein known to play a role in apoptosis, is presented.  
Interactions between DNSP-11 and the GAPDH apoptotic pathway were further 
evaluated to determine if this is a mechanism by which DNSP-11 may be 
providing some anti-apoptotic effects. 
II. Methods
a. Caspase-3 activity assay
HEK-293 cells were plated to 100,000 cells/well. Cell cultures were exposed to 
defined dosage of DNSP-11 and either 1 μM staurosporine or 8 mM 3-
nitropropionate exposure. The Enz Chek (Invitrogen) Caspase-3 kit was used to 
monitor levels of caspase-3 activity. Fluorescence measurements were made 
after 3 hours of treatment (excitation/emission 496/520 nm) using a Molecular 
Devices Spectramax M5 plate reader. Protein levels of lysed cells were 
measured by BCA assay (BioRad) and normalized for every experiment. Data 
are expressed as percent of control and were repeated a minimum of 3 times.
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b. Terminal dUTP nick-end labeling (TUNEL)
 After treatment with DNSP-11, cells are fixed and labeled to assess 
degenerative nuclear changes as indicated by the extent of high-molecular 
weight DNA strand breaks. This was performed by the Apo-BrdU TUNEL Assay 
(Invitrogen).
c. Pull down analysis with isolated substantia nigra from young Fischer 344 rats
Young F344 substantia nigra tissue samples are homogenized in Buffer A 
(20 mM HEPES, pH 7.5, 10% Glycerol, 2 mM EGTA, 2 mM EDTA, 1 mM DTT, 
CompleteTM Mini EDTA Free tablet (for 10 mL; Roche)). Samples are then 
centrifuged for 30 minutes at 100,000 x g at 4°C, and the supernatant (cytosolic 
fraction) is collected. Buffer B (Buffer A plus 0.5% Brig 58) is then added to the 
pellet, mixed thoroughly, and incubated on ice for 15 minutes. The samples are 
then centrifuged for 30 minutes at 100,000 x g at 4°C. The supernatant 
(membrane bound fraction) is then collected (pellet discarded). 50 μg of the 
bDNSP-11 is added to both the cytosolic and membrane bound fractions and 
incubated for 15 minutes on ice. The samples are then added to 125 μL aliquot of 
streptavidin magnetic beads (New England Biolabs, Beverly MA) to isolate bound 
proteins. The beads are extensively washed (three times) in 100 μL Buffer A 
(cytosolic) or 100 μL Buffer B (membrane bound). Bound proteins will be eluted 
from the beads with 2x50 μL of Solubilization/Rehydration Solution (7 M Urea, 2 
M Thiourea, 50 mM DTT, 4% CHAPS, 1% NP-40, 0.2% Carrier ampholytes, 
0.0002% Bromophenol blue) and then once with 100 μL of Solubilzation/
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Rehydration Solution.  Aliquots were pooled and the proteins are analyzed by 
2D-PAGE and identified by matrix-assisted laser desorption/ionization-time of 
flight (MALDI-TOF) mass spectrometry.
d. In Vitro Pull Down of GAPDH
Binding studies were performed using purified samples of GAPDH (Sigma) and 
bDNSP-11.  The two were incubated together in binding buffer (50 mM Tris, pH 
7.4, 150 mM NaCl, 0.1 mg/ml BSA, 50 μM NAD+, 10 mM sodium phosphate, 50 
μM Glyceraldehyde-3-phosphate) at 4°C for 1 hour. The sample were then mixed 
with streptavidin magnetic beads and incubated at 4°C for 1 hour and washed 
three times with binding buffer.  The protein was then removed from the beads 
with SDS sample running buffer.  The samples were separated by SDS-PAGE.
e. In vitro S-Nitrosylation of GAPDH
Based on the procedure described by Jaffrey et al., 2001. Pure GAPDH (Sigma) 
is pretreated with either S-nitrosoglutathione (GSNO, active NO donor) or 
glutathione (inactive control). Following incubation at RT in the dark, unreacted 
GSNO/glutathione is removed by four buffer exchanges into binding buffer (50 
mM Tris pH 7.4, 150 mM NaCl, 0.1 mg/ml BSA, 50 µM NAD+, 10 mM sodium 
phosphate, and 50 µM glyceraldehyde-3-phosphate) using a Amicon Ultra 5,000 
MWCO spin column.
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f. In vitro pull down assay
A solution of 25 µL GFRα1 (1 mg/mL) was incubated with 50 µL of 
Dynabeads® (Invitrogen) in wash and bind buffer (0.1 M sodium phosphate, pH 
8.2, 0.01% Tween® 20) for 10 minutes at room temperature.  The beads were 
then washed three times in 100 µL of wash and bind buffer.  2 µg of GDNF was 
added and incubated for 1 hour at 4°C. 25 µL GFRα1 (1 mg/mL) was incubated 
with 40 µg of biotinylated DNSP-11 (bDNSP-11) for 1 hour at 4°C. They were 
then added to 50 µL of hydrophilic streptavidin magnetic beads (New England 
Biolabs) and incubated for an hour at 4°C.
g. Western blots
Protein concentrations were determined by performing a Bradford.  
Samples were then normalized to 30 ug of total protein.  The samples were run 
on a 10% acrylamide gel for 1.5 hours at 200 volts.  The gels were then 
transferred onto PVDF membrane at 200 mA for 45 minutes.  Membranes were 
then blocked with 5% milk for 2 hours at room temperature.  After being washed 
three times for five minutes each with 1X Tris buffered saline with Tween (TSB-
T), the membranes were incubated overnight at 4°C with primary antibody.  The 
membranes were then washed three times for five minutes each with 1X TBS-T 
and incubated with the corresponding secondary antibody for 2 hours at room 
temperature.  Staining was imaged on the Odyssey and the Odyssey software 
package (LI-COR) was used to calculate the amount of protein present for 
analysis.
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III. Results
a. DNSP-11 reduces apoptosis
DNSP-11 has been shown to promote the survival of primary fetal 
mesencephalic neurons, protect from 6-hydroxydopamine (6-OHDA) toxicity in 
primary mesencephalic and MN9D dopaminergic cell culture, improve the 
neurochemical resting levels of dopamine and its metabolites for up to 28 days 
following a single injection into the rat substantia nigra, and significantly improve 
apomorphine-induced rotational behavior in a severe, PD rat model (Bradley et 
al., 2010).  Based on these data, the cellular protective effects of DNSP-11 were 
compared to that of GDNF through the use of two different measures of 
apoptosis.  Levels of apoptosis after treatment with 100 uM 6-OHDA and either 
DNSP-11 and GDNF were measured by both a TUNEL assay and a caspase-3 
activity assay.  
The TUNEL assay showed that treatment with 100 uM 6-OHDA 
significantly increased the amount of TUNEL staining that was observed.  This 
increase in TUNEL staining indicates an increase in apoptosis as measured by 
an increase in DNA fragmentation that results from apoptosis.  However, both 1 
ng/mL of DNSP-11 and GDNF were able to significantly reduce the quantity of 
TUNEL staining after a 24 hour treatment, indicating that DNSP-11 is able to 
protect the cells from apoptosis at similar levels to GDNF (Figure 4.1A).  These 
results, along with data from in vivo studies, support the hypothesis that 
DNSP-11 has a similar effect to mature GDNF.  This data was confirmed by 
caspase-3 activity assay data.  The caspase-3 activity assay also showed a 
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significant increase in the caspase-3 activity after treatment with 100 uM 6-
OHDA indicating an increase in apoptosis.  After treatment with both 1 ng/mL 
DNSP-11 and GDNF for 3 hours, levels of caspase-3 activity were significantly 
reduced (Figure 4.1B).  However, DNSP-11 did not reduce apoptosis as 
measured by caspase-3 activity at the same level as GDNF.
b. DNSP-11 does not bind GFRα1
Based on the similarities that were observed between DNSP-11’s ability to 
protect against 6-OHDA induced apoptosis and the protection offered by mature 
GDNF, the interaction between DNSP-11 and GFRα1 was evaluated in order to 
determine if DNSP-11 is functioning through the same mechanism as mature 
GDNF, which is known to function through interactions with the GFRα1 receptor. 
In order to determine if DNSP-11 interacted with GFRα1, a pull down assay was 
performed with biotinylated DNSP-11.  No interaction was observed between 
DNSP-11 and GFRα1 as indicated by the absence of GFRα1 in the elution lanes 
when DNSP-11 and GFRα1 were incubated together.  Incubation of GDNF with 
GFRα1 resulted in the expected interaction between GDNF and GFRα1, 
indicating binding of GDNF to GFRα1 by the presence of both GDNF and GFRα1 
in the elution lane (Figure 4.2).  This data indicates that DNSP-11 does not 
interact with GFRα1 in vitro and therefore, may not be mediating apoptotic 
pathways through the same mechanism as mature GDNF.
82
c. DNSP-11 does not upregulate GDNF mRNA levels
After it was observed that DNSP-11 does not bind GFRα1 in vitro, 
investigation continued in order to determine if DNSP-11’s anti-apoptotic effects 
were mediated through other mechanisms affecting overall GDNF levels.  Since 
evidence indicates that DNSP-11 did not function through the same mechanism 
as mature GDNF, it was hypothesized that DNSP-11 may provide its anti-
apoptotic effects by increasing the levels of GDNF via a positive feedback 
mechanism.  In order to further evaluate the potential mechanisms of DNSP-11’s 
action, it was evaluated whether DNSP-11 was able to influence GDNF mRNA 
levels through a feedback mechanism.  GDNF mRNA levels were determined by 
real time PCR after treatment of HEK293 cells with 1 or 10 nM DNSP-11.  There 
was no observed increase in GDNF mRNA levels during treatments with 
DNSP-11 at 6, 12, 18, and 24 hours (Figure 4.3).  
d. DNSP-11 does not upregulate GDNF protein levels
Although data suggests that DNSP-11 does not upregulate levels of GDNF 
mRNA after treatment for 6, 12, 18, and 24 hours, it is important to determine if 
DNSP-11 has any influence over the protein levels of mature GDNF after 
treatment.  In order to determine if mature GDNF protein levels were upregulated 
after DNSP-11 treatment, Western blots were performed.  MN9D cells were 
treated with either 1 or 10 nM DNSP-11 for 3, 6, 12, 18 and 24 hours.  After 
treatment, the total protein was collected from the lysed cells and analyzed by 
Western blot. 
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It was observed that there was no significant upregulation of GDNF 
protein levels under any of the tested conditions (Figure 4.4).  This indicates that 
GDNF protein levels are not influenced by the presence of DNSP-11.  Therefore, 
it is unlikely that DNSP-11 functions by a feedback mechanism that results in the 
upregulation of GDNF.  Thus, the observed in vivo and in vitro protective effects 
against 6-OHDA are likely working through a different mechanism from mature 
GDNF.
e. Proteomic analysis
Since DNSP-11 does not appear to work through the same receptor 
pathway as GDNF, nor does DNSP-11 seem to function by increasing the levels 
of GDNF mRNA or protein, it is important to determine the mechanism by which 
DNSP-11 is providing cellular protection.  In order to determine a potential 
mechanism of action, a proteomic pull down screen was performed (Figure 4.5).  
Two dimensional gel analysis following a pull down assay was used to determine 
potential binding partners.  Homogenate from rat substantia nigra were utilized 
for these studies.  Binding partners were isolated by incubation of the 
homogenate with biotinylated DNSP-11.  A pull down of the biotinylated DNSP-11 
along with its binding partners was then performed.  The binding partners were 
observed by 2D-PAGE gel analysis.  The 2D-PAGE analysis allows for proteins 
to be separated based on two properties.  The 2D-PAGE analysis used to 
evaluate the binding partners of DNSP-11 separated the proteins initially by 
differences in their molecular weights and then by the differences based on their 
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isoelectric point.  After the potential binding partners were observed on a 2D-
PAGE gel, they were then identified by matrix-assisted laser desorption/
ionization-time of flight (MALDI-TOF) mass spectrometry in the University of 
Kentucky Center of Structural Biology.  
The membrane and cytosolic protein fraction were analyzed separately 
from one another.  There was a potential binding partner observed on the 2D gel 
of the membrane fraction.  However, that potential binding partner could not be 
identified by MALDI-TOF mass spectroscopy.  
Numerous spots were observed within the cytosolic fraction of the 2D gel 
analysis (Figure 4.6; Table 4.1).  Of these sixteen observed proteins eleven of the 
potential binding partners, including aconitate hydralase, alpha enolase, 
aspartate aminotransferase, creatine kinase, fructose bisphosphate aldolase, 
glutamate dehydrogenase, glutamine synthetase, glyceraldehyde 3 phosphate 
dehydrogenase, L-lactate dehydrogenase B chain, malate dehydrogenase, and 
pyruvate kinase M1/M2, were known to have metabolic functions, while other 
binding partners played a role in the cytoskeleton, neuronal development, and 
translation.  Of the identified potential binding partners, glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was previously known to play a role in 
apoptosis (Hara, M.R. et al., 2005).  Due to the known role of GAPDH in 
apoptosis and as a target for the current PD therapeutic, deprenyl, its interactions  
with DNSP-11 were pursued further. 
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f. Confirmation of GAPDH-DNSP-11 binding
Before further analysis of GAPDH role in DNSP-11 activity was performed, 
it was important to validate the observed interaction with DNSP-11.  In order to 
confirm GAPDH-DNSP-11 binding, an in vitro pull down was performed using 
biotinylated DNSP-11 and purified GAPDH protein.  Rabbit GAPDH was 
incubated in the presence and absence of DNSP-11.  After the incubation, the 
samples were incubated with streptavidin beads to pull down the biotinylated 
DNSP-11 and anything that is bound to the DNSP-11. 
It was observed that there was binding of GAPDH to the biotinylated 
DNSP-11 as indicated by the presence of GAPDH in the elution lane on the gels 
(Figure 4.7B).  However, in the absence of DNSP-11 in the incubation, there was 
no band observed in the elution lanes of the gel (Figure 4.7A).  This indicates 
that GAPDH is not binding to the streptavidin beads nonspecifically and is in fact 
binding to DNSP-11 and therefore, would be able to play a potential role in the 
activity of DNSP-11.
g. Nitrosylation of GAPDH decreases DNSP-11 binding
In order to further evaluate the role of DNSP-11 in potentially mediating 
the GAPDH apoptotic pathway, the involvement of DNSP-11 at various steps of 
the apoptotic pathway was observed.  It is known that nitrosylation of GAPDH 
allows it to bind to Siah-1 and be transported to the nucleus.  Therefore, it is 
important to determine if DNSP-11 is able to bind to nitrosylated GAPDH and 
potentially prevent it from binding to Siah-1.  Based on the observed anti-
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apoptotic properties of DNSP-11, it was hypothesized that DNSP-11 was 
mediating this pathway by preventing the nitrosylated GAPDH from binding to 
Siah-1.  In order to determine if nitrosylation of GAPDH is able to alter it’s binding 
to DNSP-11, GAPDH was nitrosylated in vitro and then binding to biotinylated 
DNSP-11 was observed by pull down analysis.
After nitrosylation of GAPDH with GSNO for 30 minutes at 37°C, reduced 
binding of DNSP-11 to GAPDH was observed (Figure 4.8).  This was indicated by 
the reduction in the amount of GAPDH observed in the elution lanes of the gel of 
the nitrosylated GAPDH (Figure 4.8).  This observation implies that DNSP-11 
binding to GAPDH is reduced by the nitrosylation of GAPDH.  Because of this, it 
seems unlikely that DNSP-11 is mediating the GAPDH apoptotic pathway by 
interacting with nitrosylated GAPDH and preventing it from binding to Siah-1.  If 
DNSP-11 is able to mediate that GAPDH apoptotic pathway, it is likely doing so 
at another step of the pathway.
h. DNSP-11 reduces nitrosylation of GAPDH
To further evaluate DNSP-11’s role in mediating GAPDH’s apoptotic 
pathway, DNSP-11’s role in influencing the nitrosylation of GAPDH was 
observed.  In order to determine if DNSP-11 incubation influenced the 
nitrosylation of GAPDH, a GAPDH activity assay was used.  When GAPDH is not 
nitrosylated, it is able to carry out its metabolic activities.  GAPDH is an enzyme 
that plays a role in glycolysis by breaking down glucose.  This metabolic activity 
can be measured in a spectrophotometer by measuring the oxidation of NADH to 
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NAD that is a result of GAPDH activity.  Alternatively, nitrosylated GAPDH is no 
longer active and able to carry out these metabolic activities.  Therefore, an 
increase in the amount of GAPDH nitrosylation should be accompanied by a 
decrease in GAPDH activity.  If DNSP-11 does inhibit nitrosylation of GAPDH, 
then GAPDH should be able to maintain a higher level of activity in the presence 
of GSNO, which can nitrosylate GAPDH. 
When GAPDH was incubated only, enzymatic activity was observed.  
However, when GAPDH was pre-incubated with 1 mM of GSNO, no GAPDH 
activity was observed.  When GAPDH was incubated with 5 mM DNSP-11 only 
for one hour prior to measuring GAPDH activity, activity was still observed at 
similar levels as GAPDH that was not incubated with DNSP-11.  DNSP-11 was 
able to increase the amount of GAPDH activity that was observed in the 
presence of 1 mM GSNO to similar levels as what was observed in the absence 
of GSNO.  DNSP-11 was able to partially restore GAPDH activity in the presence 
of 10 mM GSNO, but at the levels of 100 mM GSNO little GAPDH activity was 
observed when 5 mM DNSP-11 was present.  This data indicates that DNSP-11 
seems to be able to inhibit the nitrosylation of GAPDH (Figure 4.9).  By blocking 
the nitrosylation of GAPDH, it is possible for DNSP-11 to modify the GAPDH 
apoptotic pathway and afford some protection to the cells from apoptosis.
i. Alteration of nuclear GAPDH levels
Previous studies have shown that during apoptosis, GAPDH levels are 
elevated in the nucleus of the cell (Hara, M.R. et al., 2005).  This elevation occurs 
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as a result of GAPDH being nitrosylated.  The nitrosylation of GAPDH allows it to 
bind to Siah-1, an E3 ubiquitin ligase.  Siah-1 has a nuclear localization signal 
that allows the GAPDH-Siah-1 complex to move into the nucleus.  GAPDH helps 
to stabilize Siah-1, which is normally quickly degraded and, therefore, not 
normally present in the nucleus for extended periods of time.  However, when it is  
bound to GAPDH, Siah-1 is stabilized and can then degrade its nuclear targets, 
leading to apoptosis.  In order to determine if DNSP-11 is mediating the pathway, 
nuclear GAPDH levels were observed by Western blot analysis of samples after 
treatment with toxin either with or without DNSP-11.  
In MN9D cells it was observed that DNSP-11 decreased the amount of 
nuclear GAPDH that was observed after treatment with 20 μM 6-OHDA for 18 
hours (Figure 4.10).  However, due to the fact that the MN9D cells showed high 
levels of cell death as a result of treatment with 6-OHDA, studies were moved 
into HEK293 cells, a more stable cell line.  Treatment of HEK293 cells 100 μM 
etoposide resulted in an increase in nuclear GAPDH after 24 hours of treatment 
(Figure 4.11, Figure 4.12).  However, western blots showed no significant 
decrease in nuclear GAPDH when these cells were treated with either 1 or 10 nM 
of DNSP-11 (Figure 4.11, Figure 4.12).
Recent studies have indicated that the effects of DNSP-11 occur more 
quickly than originally hypothesized with the peptide being internalized within 
minutes of treatment.  Therefore, the studies performed in MN9D cells at 18 
hours post treatment may have been to late to see any observed changes in 
nuclear GAPDH levels.  Based on this observation, studies have been carried out 
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to evaluated nuclear GAPDH levels at shorter time periods.  It has been noted 
that nuclear GAPDH is elevated after treatment for 5 minutes with both 1 μM 
staurosporine and 20 μM 6-OHDA.  However, no changes in nuclear GAPDH 
were observed in cells treated with 8 mM 3-NP at this time point.  Treatment with 
100 nM DNSP-11 was able to reduce nuclear GAPDH levels after staurosporine 
treatment only (Figure 4.13, Figure 4.14).  At this time point, changes in cytosolic 
GAPDH were not observed (Figure 4.13, Figure 4.14).  These studies indicate a 
need to evaluate the actions of DNSP-11 at shorter time periods.
IV. Discussion
It has been observed that DNSP-11 is able to provide protection from 
apoptosis.  Here data has been presented to show that DNSP-11 is able to 
protect from 6-OHDA induced apoptosis.  DNSP-11 has been shown to reduce 
the levels of apoptosis similarly to the reduction in apoptosis that has been 
observed after treatment with GDNF.  Two different apoptotic screens were used 
to evaluate this.  Measurements of both TUNEL staining and caspase-3 activity 
levels showed a significant reduction of apoptosis in 6-OHDA treated MN9D 
cells.  Since DNSP-11 is able to reduce apoptosis to similar levels as GDNF, it is 
reasonable to hypothesis that DNSP-11 may be functioning through the same 
pathway as GDNF.   
Mature GDNF is known to promote cell survival through its binding to the 
receptor GFRα1.  To test if DNSP-11 was providing protection from apoptosis 
through the same mechanism as mature GDNF, a pull down assay with 
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biotinylated DNSP-11 and GFRα1 was performed.  This assay will allow for 
determination of DNSP-11’s ability to bind with GFRα1, potentially allowing for 
DNSP-11 to function by signaling through the GFRα1 receptor.  DNSP-11 was 
not observed to bind to GFRα1, while the mature GDNF was shown to bind to 
GFRα1 as expected.  Since DNSP-11 does not interact with GFRα1, it suggests 
the DNSP-11 does not function through the binding to GFRα1 in a similar 
mechanism as mature GDNF, meaning that while DNSP-11 is able to protect 
from apoptosis similarly to mature GDNF, it likely does so through the  
mechanism unique from that of mature GDNF.  
Since DNSP-11 has been shown to not interact with GFRα1 in vitro, it is 
hypothesized that it functions through a different mechanism than mature GDNF 
to offer protective effects.  Based on this hypothesis, the role of DNSP-11 in a 
potential feedback mechanism with GDNF was evaluated.  Because the cellular 
protection that was observed with both GDNF and DNSP-11 were similar, it is 
reasonable to hypothesize that DNSP-11 may provide this protection by 
upregulating the levels of mature GDNF.  Therefore, the observed protection is a 
result of the increase in GDNF levels.  In order to test this hypothesis, studies 
were performed to determine if treatment with DNSP-11 resulted in changes in 
GDNF at both the mRNA and protein levels.  After treating MN9D cells for 6-24 
hours with either 1 or 10 nM DNSP-11, no significant increase in GDNF mRNA 
levels were observed.  DNSP-11 does not appear to be initiating a feedback 
mechanism that influences the levels of GDNF mRNA.  In addition, there was no 
significant increase in GDNF protein levels after treatment with 1 or 10 nM 
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DNSP-11 for between 3-24 hours.  Since neither GDNF mRNA nor protein levels 
were increased by DNSP-11 treatment, it can be concluded that DNSP-11 does 
not function by initiating a feedback mechanism resulting in an upregulation in 
GDNF mRNA or protein.  This feedback pathway would result in an increase in 
GDNF levels, which could lead to an increased activation of the GFRα1 pathway, 
resulting in the observed reduction in apoptosis. 
Collectively these data support the hypothesis that DNSP-11 may not 
function through the same mechanism as mature GDNF by interacting with 
GFRα1.  It has also been shown that DNSP-11 does not function to upregulate 
GDNF, either at the mRNA or protein level.  These data indicate that DNSP-11 is 
functioning by a mechanism that is distinct from that of mature GDNF.  
In order to determine by what mechanism DNSP-11 is functioning, a proteomic 
screen of potential binding partners was performed.  A two-dimensional gel 
analysis was performed with young Fischer 344 rat substantia nigra homogenate. 
The observed binding partners on the gels were then identified by MALDI-TOF 
mass spectroscopy.  Both the membrane and cytosolic fractions were evaluated 
during this process.  None of the observed binding partners in the membrane 
fraction could be identified.  However, within the cytocolic fraction, sixteen 
proteins were identified.  Of these sixteen proteins eleven of the potential binding 
partners, including aconitate hydralase, alpha enolase, aspartate 
aminotransferase, creatine kinase, fructose bisphosphate aldolase, glutamate 
dehydrogenase, glutamine synthetase, glyceraldehyde 3 phosphate 
dehydrogenase, L-lactate dehydrogenase B chain, malate dehydrogenase, and 
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pyruvate kinase M1/M2, were known to have metabolic functions.  Further, 
proteins with additional functions such as chaperones (heat shock cognate 71 
kDa protein), cytoskeletal proteins (actin and tubulin), neuronal development 
(dihydropyrimidinase-related protein 2), and translation (elongation factor-1 alpha 
2) were identified.  Of the potential binding partners that were identified, one,
GAPDH, was known to play a role in apoptosis, in addition to being a key 
metabolic protein.  Because of GAPDH’s known role in apoptosis, its interaction 
with DNSP-11 was further evaluated for a potential role in offering cellular 
protection that has been observed with DNSP-11 treatment. 
In order to confirm binding between DNSP-11 and GAPDH, an in vitro pull 
down with biotinylated DNSP-11 and purified GAPDH was performed.  This pull 
down showed that biotinylated DNSP-11 was able to bind to the purified GAPDH 
further supporting the idea that DNSP-11 and GAPDH interact with one another 
and that this interaction may be able to mediate apoptotic pathways.  Verifying 
GAPDH as a DNSP-11 binding partner allows for the further investigation of 
GAPDH in DNSP-11’s anti-apoptotic activities.
GAPDH is known to play a role in an apoptotic pathway that involves 
GAPDH interacting with Siah-1, an E3 ubiquitin ligase.  This pathway allows for 
an increase in nuclear GAPDH and Siah-1 because of the binding of Siah-1 to 
GAPDH after nitrosylation of GAPDH has occurred.  Siah-1’s nuclear localization 
signal allows the complex to be transported to the nucleus, where it is stabilized 
and longer lasting degradation of Siah-1’s nuclear targets leads to apoptosis.  
Therefore, one of the markers that can be used to evaluate this pathway is the 
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nuclear level of GAPDH.  If this apoptotic pathway is being activated, the amount 
of GAPDH in the nucleus should be elevated (Hara, H.R. et al., 2005).  In order 
to determine if DNSP-11 was interacting with the GAPDH apoptotic pathway, 
Western blots of the nuclear fraction of GAPDH were evaluated after treatment 
with toxins which elevated the activation of the GAPDH apoptotic pathway.
In order to determine if the interaction of DNSP-11 and GAPDH plays a role in 
mediating apoptosis, the interaction of DNSP-11 with GAPDH at different stages 
of the GAPDH-Siah-1 pathway were investigated.  Since nitrosylation of GAPDH 
is an initiating factor in this pathway, it was important to determine if DNSP-11 
was able to influence the nitrosylation of GAPDH.  Also, interaction of DNSP-11 
with GAPDH after nitrosylation had occurred was evaluated in order to determine 
if DNSP-11 was able to bind to nitrosylated GAPDH and prevent it from binding to 
Siah-1 which would result in a reduction of GAPDH-Siah-1 complex formation 
and therefore, nuclear transport.
To gain insight into DNSP-11’s effects on GAPDH, we evaluated the 
interaction between DNSP-11; GAPDH, after it was nitrosylated, was evaluated 
to determine if DNSP-11 binds nitrosylated GAPDH to inhibit the formation of the 
GAPDH-Siah-1 complex.  GAPDH was nitrosylated with GSNO prior to 
incubation with biotinylated DNSP-11.  After nitrosylation of GAPDH, it was 
incubated with biotinylated DNSP-11 and a pull down assay was performed.  This 
pull down assay showed that binding between biotinylated DNSP-11 to GAPDH 
after nitrosylation with GSNO was reduced.  The reduction in binding that was 
observed implies that DNSP-11 does not interact with nitrosylated GAPDH.  
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Therefore, it does not likely bind to nitrosylated GAPDH to inhibit it from 
interacting with Siah-1.  It also suggests that DNSP-11 is unlikely to bind to 
nitrosylated GAPDH when it is part of the GAPDH-Siah-1 complex and, therefore 
inhibiting the nuclear localization of the complex. 
The role in DNSP-11 in the nitrosylation of GAPDH was then evaluated.  
Since nitrosylation of GAPDH is required for binding to Siah-1, if DNSP-11 is able 
to inhibit the nitrosylation of GAPDH, it could prevent it from binding to Siah-1 
and, therefore, reduce apoptosis.  Since nitrosylation of GAPDH also results in it 
losing its metabolic activity, activity assays of GAPDH were used to evaluate the 
level of GAPDH nitrosylation after treatment with GSNO.  It was observed that 
incubation with DNSP-11 allowed for GAPDH to remain active even in the 
presence of the nitrosylating agent, GSNO.  The ability of DNSP-11 to inhibit 
nitrosylation of GAPDH could allow for it to prevent the activation of the GAPDH 
apoptotic pathway.  This could contribute to the beneficial cellular effects of 
DNSP-11 that have been observed.
It was observed that in HEK 293 cells, 100 μM staurosporine was able to 
elevate the levels of GAPDH in the nuclear fractions of these cells after 24 hours 
of treatment.  In HEK 293 cells treated with either 1 or 10 nM DNSP-11 for 24 
hours along with 100 μM staurosporine, there was no significant reduction in 
nuclear GAPDH levels observed.  This indicates that the interaction with the 
GAPDH apoptotic pathway may not be solely involved in DNSP-11’s ability to 
reduce apoptotic levels.  Since such a large number (eleven of sixteen) of the 
identified DNSP-11 binding partners play a role in metabolism, DNSP-11 may 
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provide protection by influencing these pathways.  There is evidence that 
DNSP-11 plays a protective role in mitochondrial mechanisms of cell death.  
Additional data from MN9D cells indicates that changes in nuclear GAPDH may 
occur at an earlier time points than originally hypothesized.  It has been observed 
that DNSP-11 is able to reduce nuclear GAPDH levels after treatment with 
staurosporine for only 5 minutes.  Based on this information, it is probable that 
GAPDH mechanism might be an early protective mechanism with other 
mitochondrial mechanisms playing a role later in the protection.
V. Conclusion
It has been observed that DNSP-11 is capable of providing anti-apoptotic 
effects in cellular toxin models of apoptosis if it is able to reduce apoptotic levels 
similarly to GDNF.  However, it appears to work by a mechanism that is unique 
from mature GDNF.  We have shown that DNSP-11 is able to interact in vitro to a 
variety of proteins, the majority of which have known metabolic functions.  
Because of its known role in regulating apoptosis and metabolic pathways, we 
investigated the role of DNSP-11 in mediating the GAPDH apoptotic pathway.  
While it has been noted that high concentrations of DNSP-11 are able to inhibit 
nitrosylation of GAPDH, we did not observe a significant reduction in nuclear 
GAPDH in HEK 293 cells.  It seems that DNSP-11’s interaction with GAPDH may 
play a role in the reduction of apoptosis, but is likely not the only mechanism by 
which DNSP-11 is able to afford protection from apoptosis.  The interaction with 
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numerous other metabolic proteins indicates that DNSP-11 may play a broader 
role in these metabolic pathways.  
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Figure 4.1: Protective effects of DNSP-11 and GDNF against 6-OHDA. Both 
DNSP-11 and GDNF protect against 6-OHDA toxicity as demonstrated by 
reductions in TUNEL staining at 24 h (A) and caspase-3 (B) activity at 3 h after 6-
OHDA exposure. MN9D dopaminergic cells were incubated for 1 hour with either 
citrate buffer (control), 1 ng/mL of DNSP-11 or GDNF prior to 100 µM 6-OHDA 
exposure for 15 min. Data are + SD, one-way ANOVA with Tukey's post hoc 
analysis, *p<0.05, **p<0.01, ***p<0.001 vs. control; #p<0.05, ##p<0.01, 
###p<0.001 vs. 6-OHDA (Modified from Bradley et al., 2010). 
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Figure 4.2: DNSP-11 does not bind to GFRα1. When GFRα1 was incubated with 
bDNSP-11 no interaction was observed as indicated by the GFRα1 being found 
in the flow through (F) lane and absent in the elution (E) lane.  However, 
incubation of GDNF with GFRα1 resulted in an observed interaction between 
GDNF and GFRα1 as shown by the presence of both GDNF and GFRα1 in the 
elution lane. 
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Figure 4.3: Effects of DNSP-11 on GDNF mRNA levels. After treatment of 
HEK293 cells with 1 nM DNSP-11 for 6, 12, 18, and 24 hours, (A) shows that 
there was no significant increase in GDNF mRNA levels as measured by real 
time PCR. Similar results were observed after treatment with 10 nM DNSP-11 for 
6, 12, 18, and 24 hours (B).
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Figure 4.4: Effects of DNSP-11 on GDNF protein levels. (A) shows a Western 
blot analysis of the GDNF in MN9D after treatment with DNSP-11. (B) shows that 
there was no significant changes in the levels of GDNF after treatment with 1 nM 
DNSP-11 for 3,6,12,18, and 24 hours. (C) shows similar results of no increase in 
GDNF after treatment with 10 nM DNSP-11 for 3, 6, 12, 18, and 24 hours. 
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Figure 4.5: Proteomic pull down with biotinylated DNSP-11. A proteomic pull 
down with biotinylated DNSP-11 was preformed as described here. Homogenate 
from rat substantia nigra was incubated with biotinylated DNSP-11 and a pull 
down was performed. The potential binding partners were isolated by 2D PAGE 
analysis and identified by MALDI-TOF mass spectrometry.
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Figure 4.6: Potential binding partners for DNSP-11. The cytosolic fraction isolated 
from rat substantia nigra was used to carry out a pull down assay. The potential 
binding partners were separated by 2D PAGE analysis with the gel shown here. 
The proteins isolated were then submitted for identification by MALDI-TOF mass 
spectroscopy.
103
Table 4.1: Potential binding partners for DNSP-11. The potential binding partners 
of DNSP-11 identified in the cytosolic fraction are shown here along with their 
primary function. The majority of the proteins identified play a role in metabolism, 
indicating that DNSP-11 may play a role in mediating metabolic pathways 
(Modified from Bradley et al., 2010).
Protein Primary Function
Aconitate Hydralase Metabolism
Alpha Enolase Metabolism
Aspartate Aminotransferase Metabolism
Creatine Kinase Metabolism
Fructose Bisphosphate Aldolase Metabolism
Glutamate Dehydrogenase Metabolism
Glutamine Synthetase Metabolism
Glyceraldehyde 3-Phosphate Dehydrogenase Metabolism/Apoptosis
L-Lactate Dehydrogenase B Chain Metabolism
Malate Dehydrogenase Metabolism
Pyruvate Kinase M1/M2 Metabolism
Heat Shock Cognate 71kDa Protein Chaperone
Actin Cytoskeleton
Tubulin Cytoskeleton
Dihydropyrimidinase-Related Protein 2 Neuronal Development
Elongation Factor-1 Alpha 2 Translation
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Figure 4.7: DNSP-11’s interaction with GAPDH. An in vitro pull down was 
performed with purified GAPDH and biotinylated DNSP-11 (B). When the pull 
down was done in the absence of DNSP-11 (A), no GAPDH was pulled down. M: 
Precision Plus Protein Standard, FT: Flow through, W3: Wash three, E1: Elution 
one, E2: Elution two, E3: Elution three. 
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Figure 4.8: Effect of GAPDH nitrosylation on DNSP-11 binding. GAPDH 
nitrosylation by GSNO was able to reduce the binding of GAPDH to DNPS-11 as 
show be a reduction in GAPDH present in E3 after treatment with GSNO in the 
presence of DNSP-11 compared to GAPDH that was not pretreated with 
DNSP-11. M: Precision Plus Protein Standard, FT: Flow through, W3: Wash 
three, E1: Elution one, E2: Elution two, E3: Elution three.
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Figure 4.9: Nitrosylation of GAPDH with varying GSNO concentrations. GAPDH 
incubated alone (blue diamonds) showed enzymatic activity.  When GAPDH was 
pre-incubated with 1 mM of GSNO (pink squares), no GAPDH activity was 
observed.  When GAPDH was incubated with 5 mM DNSP-11 only (pink 
asterisks) for one hour prior to measuring GAPDH activity, activity was still 
observed at similar levels as GAPDH that was not incubated with DNSP-11.  
DNSP-11 was able to increase the amount of GAPDH activity that was observed 
in the presence of 1 mM GSNO (red circles) to similar levels as what was 
observed in the absence of GSNO.  DNSP-11 was able to partially restore 
GAPDH activity in the presence of 10 mM GSNO (green crosses), but at the 
levels of 100 mM GSNO (blue dashes) little GAPDH activity was observed when 
5 mM DNSP-11 was present.  
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Figure 4.10: Effects of DNSP-11 on nuclear GAPDH levels in MN9D cells. 
Nuclear GAPDH was reduced in MN9D cells after treatment with 1 or 10 ng/mL 
DNSP-11 and 20 μM 6-OHDA compared to cells treated only with 20 μM 6-
OHDA .
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Figure 4.11: Effects of DNSP-11 on nuclear GAPDH levels in HEK293 cells. 
Western blots showed that treatment of HEK293 cells 100 μM etoposide resulted 
in an increase in nuclear GAPDH after 24 hours of treatment.  However, no 
significant decrease in nuclear GAPDH was observed when these cells were 
treated with either 1 or 10 nM of DNSP-11 for 24 hours.
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Figure 4.12: Effects of DNSP-11 on nuclear GAPDH levels in HEK293 cells. 
Western blots showed that treatment of HEK293 cells 100 μM etoposide resulted 
in an increase in nuclear GAPDH after 24 hours of treatment.  However, no 
significant decrease in nuclear GAPDH was observed when these cells were 
treated with either 1 or 10 nM of DNSP-11 for 24 hours.
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Figure 4.13: Effects of DNSP-11 on nuclear GAPDH levels after 5 minute 
treatments in MN9D cells.  Treatment of MN9D cells with either 8 mM 3-NP, 1 μM 
staurosporine, or 20 μM 6-OHDA resulted in an increase in nuclear GAPDH.  
Treatment with 100 nM DNSP-11 after staurosporine treatment resulted in a 
reduction in nuclear GAPDH. Lane 1: Control, Lane 2: 8 mM 3-NP, Lane 3: 1 μM 
Staurosporine, Lane 4: 8 mM 3-NP and 100 nM DNSP-11, Lane 5: 1 μM 
Staurosporine and 100 nM DNSP-11, Lane 6: 100 nM DNSP-11, Lane 7: 20 μM 
6-OHDA, Lane 8: 20 M 6-OHDA and 100 nM DNSP-11 (Data obtained by Dr. 
Turchan-Cholewo).
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Figure 4.14: Changes in nuclear GAPDH levels in MN9D cells.  No changes were 
observed in cytosolic GAPDH levels after treatment with 8 mM 3-NP, 1 μM 
staurosporine, or 20 μM 6-OHDA.  However, increases in nuclear GAPDH levels 
were observed after treatment with 1 μM staurosporine or 20 μM 6-OHDA.  The 
levels of nuclear GADH were reduced after treatment with 100 nM DNSP-11. 
Data are + SD, one-way ANOVA with Tukey's post hoc analysis, *p<0.05 vs. 
control; #p<0.05 vs. Staurosporine (Data obtained by Dr. Turchan-Cholewo).
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Chapter Five: Conclusions and future directions
I. Introduction
Several obstacles accompany the treatment of neurodegenerative 
disease.  These obstacles are often associated with the delivery of therapeutic 
agents to the central nervous system.  The treatment of Parkinson’s disease (PD) 
has not been an exception.  Previous studies evaluating potential treatments for 
PD, including clinical trials with glial cell line-derived neurotrophic factor (GDNF), 
have faced issues associated with the delivery of a large protein to the brain (Gill 
et al., 2003; Slevin et al., 2005; Lang et al., 2006).  These complications have 
resulted in a need to develop molecules that have the same protective effects as 
GDNF, but that have the potential for less invasive methods for delivery.  The 
development and evaluation of the DNSPs has shown that they possess 
characteristics that make them viable lead-candidates for potential therapeutics 
including their size, solubility, stability, and protective effects.
II. Introduction of alternative mechanisms
Data presented here has shown that DNSP-11 is able to protect against 
apoptosis.  The ability of DNSP-11 to reduce apoptosis levels in cellular models, 
along with the small size and long-term stability of the molecule, make DNSP-11 
of interest as a potential therapeutic for PD.  As a smaller molecule, DNSP-11 
offers an advantage over larger molecules for synthesis and delivery and was 
shown to be stable for out to one month under a variety of storage conditions, 
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including -80°C and 37°C.  These data also provide information about the lack of 
aggregation of the peptide in solution.  The development of aggregations can 
prevent the peptides from advancing through development as a potential 
therapeutic agent because it increases the likelihood that it triggers an immune 
response.  Together these data make the peptide a viable candidate for future 
development as a potential therapeutic molecule.
Since it has been observed that DNSP-11 is able to provide anti-apoptotic 
effects, the investigation into the mechanism by which DNSP-11 is able to 
provide these effects became important.  It was determined that DNSP-11 did not 
function through the same mechanism as mature GDNF - since it was shown to 
not bind to GFRα1.  These data are further supported by the differential 
protective effects against staurosporine that have been observed (Bradley et al., 
2010).  DNSP-11 was also shown to not function through a feedback mechanism 
involving an upregulation of either GDNF mRNA or GDNF protein levels.  Sixteen 
cytosolic proteins were identified as potential binding partners.  Of these 
identified proteins, one, GAPDH, was known to play a role in apoptosis.  After 
further evaluation of the interactions between DNSP-11 and GAPDH, it was 
observed that DNSP-11 could inhibit nitrosylation of GAPDH; however, it was not 
able to significantly reduce nuclear localization of GAPDH.  This implies that 
while the interaction with GAPDH may play a contributing role in DNSP-11’s anti-
apoptotic activity, it is not likely the only mechanism by which DNSP-11 helps to 
reduce apoptosis.
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If DNSP-11 is not providing its anti-apoptotic effects only through 
interactions with GAPDH, then it is likely that its interactions with other identified 
binding partners play at least a contributing role, if not the primary role, in 
DNSP-11’s observed anti-apoptotic effects.  One possible scenario is that 
DNSP-11 is able to interact with multiple metabolic binding partners that have 
been identified through a proteomic screen for a combined anti-apoptotic effect.  
Additionally, there is evidence that DNSP-11 has mitochondrial effects that are 
not observed after treatment with GAPDH, indicating that this mechanism is 
unique for DNSP-11.  These mitochondrial effects may allow for an overall 
reduction in oxidative damage and lead to a reduction in levels of apoptosis.  
Further evaluation of these potential mechanisms is required to determine what 
their roles are in DNSP-11’s anti-apoptotic activities.
III. Metabolic binding partners
In order to determine the potential binding partners of DNSP-11, a 
proteomic pull down assay was carried out.  This assay identified sixteen proteins 
as potential binding partners of DNSP-11.  The majority of these proteins are 
known to play a role in cellular metabolism.  Because of the number of potential 
DNSP-11 binding partners that have been identified as  playing a role in cellular 
metabolism, it is likely that DNSP-11, in mediating cellular metabolism, not only 
interacts with GAPDH, but may play a broader role as well.  
While interaction between GAPDH and DNSP-11 were observed and 
confirmed, it seems likely that this interaction is not the sole source of the 
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observed anti-apoptotic effect that has been associated with treatment with 
DNSP-11.  This broad mechanism may allow for DNSP-11 to interact with 
multiple binding partners with each of these interactions contributing in part to the 
overall observed effect. Therefore, while interactions with GAPDH may not be the 
primary source of protection, it may play a role in this combined mechanism.
a. Glutamate dehydrogenase
One example of an additional protein that has also been identified as a 
potential binding partner of DNSP-11 is glutamate dehydrogenase.  Glutamate 
dehydrogenase is located within the mitochondria of cells.  This enzyme 
functions in the interconversion of glutamate to α-ketoglutarate.  This reaction 
also involves the conversion of NAD+ to NADH.  Due to the change in NADH/
NAD+ levels, this reaction can be monitored through the use of a 
spectrophotometer.  
Studies were carried out looking at DNSP-11’s effects on glutamate 
dehydrogenase activity.  These in vitro studies involved treating glutamate 
dehydrogenase with DNSP-11 and then evaluating its kinetic activity.  It was 
observed that the presence of DNSP-11 reduced the activity of glutamate 
dehydrogenase.  This study provides us with evidence that some of the 
additional potential binding partners that have been identified through the 
proteomic binding study play a role in mediating the observed anti-apoptotic 
effects of DNSP-11.
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Additional evaluation of the other identified potential binding partners with 
metabolic functions is required to get a complete picture of the full extent of the 
anti-apoptotic effects of DNSP-11.  These studies can help to further reveal the 
complex nature of DNSP-11’s protective activity.  By providing further information 
about DNSP-11’s mechanism, these studies will provide us with the necessary 
foundation for further studies to evaluate its full potential as a therapeutic agent.
IV. Mitochondrial interactions
It has been observed that DNSP-11 is able to protect from 6-OHDA 
induced apoptosis, similar to what has been observed in studies with mature 
GDNF.  However, DNSP-11 offers protection from additional toxins that mature 
GDNF has been shown not to provide.  Studies have been carried out evaluating 
the DNSPs’ (DNSP-5, DNSP-11, and DNSP-17) ability to provide protection from 
several mitochondrial toxins.  It was observed that DNSP-11 offered the most 
significant protection from these toxins, including staurosporine and 3-
nitropropionic acid (3-NP).  This observation led to the further evaluation of 
DNSP-11’s protection from mitochondrial involvement. 
It was observed that 10 ng/mL DNSP-11 was able to protect B65 cells, a 
dopaminergic cell line, from 1mM staurosporine during a 20 hour treatment by 
approximately 125% as measured by LIVE/DEAD assay.  DNSP-11 was able to 
significantly reduce the observed staurosporine-induced cytotoxicity.  However, 
treatment with 10 ng/mL GDNF did not provide significant protection from 
staurosporine-induced cytotoxicity.  Similarly, DNSP-11 was able to provide 
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protection from gramicidin-induced cytotoxicity.  DNSP-11 was able to reduce 
gramicidin-induced cytotoxicity after treatment with 1mM gramicidin for 20 hours 
by approximately 60% compared to the control.  In contrast, GDNF was not able 
to protect the B65 cells from gramicidin.  This study indicates that there are 
distinct differences between the mechanisms by which GDNF and DNSP-11 
provide their observable beneficial effects, despite being derived from the same 
parent molecule. 
The release of cytochrome c from the mitochondria is associated with 
mitochondrial apoptosis.  The release of cytochrome c can be used to measure 
the relative levels of the associated mitochondrial apoptosis.  Studies looking at 
the staurosporine-induced release of cytochrome c after treatment with either 
DNSP-11 or GDNF have been carried out.  It was observed that treatment with 
DNSP-11 was able to reduce the amount of cytochrome c that was released from 
the mitochondria.  However, no reduction in cytochrome c release was observed 
after treatment with mature GDNF.  This further indicates that DNSP-11 functions 
via a mechanism distinct from mature GDNF.  This unique mechanism appears to 
involve a role in mediating mitochondrial apoptosis.
These studies indicate that DNSP-11 can offer broad mitochondrial 
protection in cellular models.  Based on data about the potential binding partners 
of DNSP-11, it is likely that DNSP-11’s interactions with multiple metabolic 
binding partners is responsible for these protective effects.  In addition to these 
studies, there is data indicating that DNSP-11 is able to affect the mitochondrial 
respiration rate, which has also not been previously observed with mature GDNF.  
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V. Combination of mechanisms
Since significant reductions in the levels of nuclear GAPDH were not 
observed after treatment with DNSP-11 in HEK-293 cells, it is likely that DNSP-11 
does not offer its observed anti-apoptotic effects through this single mechanism.  
Evidence that DNSP-11 is able to reduce the amount of GAPDH nitrosylation that 
is observed indicates that DNSP-11 could be altering the GAPDH’s interaction 
with Siah-1 even if this does not result in significant reductions in nuclear 
GAPDH.  Based on this data along with other data looking at DNSP-11’s effects 
on the mitochondria, it is likely that DNSP-11 interacts with multiple partners, not 
just GAPDH, to provide its anti-apoptotic effects.  
Since many of the binding partners that were observed during the 
proteomic binding assay have known metabolic functions, it may be 
hypothesized that DNSP-11 has a broader metabolic effect.  Through interactions 
with these proteins, DNSP-11 may influence multiple pathways to provide an 
overall protective effect.  Evidence that DNSP-11 is able to affect mitochondrial 
pathways by mechanisms that are unique from that of GDNF supports the idea 
that DNSP-11 is functioning by a mechanism unique from that of GDNF.
VI. Future directions
a. GAPDH
While the interaction with GAPDH does not appear to be the only 
mechanism by which DNSP-11 is able to offer its protective effects, this 
interaction does appear to alter the activity of GAPDH.  Data presented here 
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indicates that DNSP-11 is able to bind to non-nitrosylated GAPDH and alter its 
activity within the apoptotic pathway.  The binding of DNSP-11 to GAPDH 
reduces the nitrosylation of GAPDH, which is necessary for GAPDH binding to 
Siah1 to activate apoptosis.  It was observed that this interaction was not able to 
significantly reduce nuclear GAPDH, a marker of this apoptotic pathway, in HEK 
293 cells after 24 hour treatment; however, reductions in nuclear GAPDH were 
observed in MN9D cells after 5 minutes of treatment with staurosporine and 
DNSP-11.  These data indicate that the 24 hour timeframe was to long for the 
GAPDH mechanism to be effective.  Based on this, future studies could be 
carried out at shorter time periods to determine if GAPDH plays an early role in 
the observed anti-apoptotic effects of DNSP-11.
i. C150 mutation of GAPDH experiments
When GAPDH is involved in initiating apoptosis, GAPDH is nitrosylated at 
cysteine 150 (C150) (Hara et al., 2005).  This nitrosylation allows for the binding 
between GAPDH and Siah1 and therefore, the nuclear localization of GAPDH.   
The nuclear localization of GAPDH is a marker of the apoptotic pathway.  
Studies to evaluate DNSP-11’s interaction with C150 could be carried out to 
further evaluate its role in mediating this apoptotic pathway.  C150 of GAPDH 
can be mutated and binding studies between the mutated GAPDH and DNSP-11 
can performed.  These studies will provide information about the importance of 
C150 in the binding of DNSP-11 to GAPDH.  It is hypothesized that this site on 
GAPDH is involved in the interaction between DNSP-11 and GAPDH since it has 
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been observed that nitrosylation of GAPDH, which has been shown to occur at 
C150 (Hara et al., 2005), has been shown to reduce the binding of DNSP-11 to 
GAPDH.
These studies will provide further insight into the interactions between 
DNSP-11 and GAPDH.  This will allow for a better understanding of how 
DNSP-11 is able to mediate GAPDH’s role in apoptosis and potentially provide 
insight into why this interaction is not able to completely inhibit nuclear 
localization of GAPDH.
b. Glutamate dehydrogenase
The identification of DNSP-11’s potential binding partners resulted in data 
indicating that DNSP-11 interacts with a variety of metabolic proteins, including 
glutamate dehydrogenase (GDH).  Additional studies have shown that the 
interaction between DNSP-11 and GDH is able to reduce the activity of GDH.  
Further evaluation of GDH’s interaction with DNSP-11 can provide insight into 
how the interaction between DNSP-11 and GDH is able to alter the activity of 
GDH.  By further understanding the role of DNSP-11 in modifying the activity of 
GDH, insight into how DNSP-11 is able to affect apoptotic pathways can be 
provided.  
c. Evaluation of other binding partners
To date, only two of the potential binding partners identified during the 
proteomic pull down assay have been further investigated for a potential role in 
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apoptosis.  By evaluating the interaction of DNSP-11 with some of these 
additional proteins, insight into potential involvement of multiple mechanisms in 
the observed protective effects of DNSP-11 can be explored.
Additional studies can be carried out to further evaluate the roles of each 
of these potential binding partners.  First, binding studies can be done to 
determine if DNSP-11 is actually able to interact with each of the potential 
binding partners.  These studies would provide data that would help to determine 
which interactions should be further evaluated.  Once those binding partners 
have been identified, studies to look at how the interaction with DNSP-11 affects 
their activity can be performed.  If the data indicates that DNSP-11 is able to 
affect the activity of these binding partners, further studies can provide 
information about the mechanism of action.
Finally, studies to look at DNSP-11’s overall role in metabolism will provide 
further insight into how the interactions with multiple binding partners can affect 
the metabolic pathways in vitro.  The interaction with numerous metabolic 
proteins indicates that DNSP-11 may play an important role in modifying multiple 
pathways involved in metabolism.  Understanding the modification of metabolic 
pathways by DNSP-11 may play an important role in providing a more 
comprehensive understanding of the role of DNSP-11 in apoptosis. 
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